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Medication Nonadherence, Health Care Utilization, and SafeMed Care Transitions
Model Impact in Super-Utilizers
Abstract
BACKGROUND: Super-utilizers are individuals with disproportionately high inpatient and emergency
department (ED) use, and mostly have multiple chronic conditions and use multiple concurrent
medications. They place a substantial burden on the U.S. healthcare system and have become the focus
of policy initiatives aimed at reducing their disproportionate inpatient and ED use. Medication
management is critical for these patients since nonadherence to essential chronic medications is
associated with poor health outcomes, and higher health care utilization and costs. OBJECTIVES: This
dissertation employed a three empirical research papers approach to study the following aims: (1) the
prevalence and patterns of medication nonadherence to essential chronic medications in Medicare superutilizers with chronic conditions, and to identify the factors associated with medication nonadherence,
with special emphasis on factors including mental illness and use of opioid medications, (2) examine
associations between medication nonadherence, and inpatient and ED use, and to evaluate other risk
factors associated with health care utilization in Medicare super-utilizers with chronic conditions, and (3)
examine the impact of the SafeMed Program, a care transitions program with a focus on medication
management, on medication use and adherence among publicly insured super-utilizers with chronic
conditions. METHODS: This dissertation was based on patients eligible for the SafeMed Program, a care
transitions program with a focus on medication management. The SafeMed Program targeted publicly
insured super-utilizers with chronic conditions who were admitted to three hospitals that were part of a
non-profit hospital system in Memphis, TN. The study sample included Medicare or TennCare insured
adults who met the SafeMed Program eligibility criteria, had continuous medication coverage, and filled at
least one of the drug classes used to treat hypertension, congestive heart failure, coronary artery disease,
diabetes mellitus, chronic obstructive pulmonary disease (COPD), or asthma. Papers 1 and 2 were
retrospective panel data analyses of the 2-year baseline data for Medicare Part D beneficiaries meeting
the SafeMed Program eligibility criteria. Association between various factors and medication
nonadherence was examined using random effects models with a binary distribution. Association
between medication nonadherence and inpatient and ED utilization was examined using fixed effects
negative binomial analyses. Paper 3 used a prospective quasi-experimental study design to examine the
effectiveness of the SafeMed Program on medication use and adherence among SafeMed participants
compared with patients in a control group using a difference in differences (DID) approach. RESULTS:
Paper 1 demonstrated that the proportion of patients who were nonadherent to their essential chronic
disease medications ranged from 45.7% to 58.4%, with the highest rate for COPD/Asthma medications
(54.3% to 64.4%). In the multivariate analysis examining predictors of medication nonadherence, we
found that compared with patients who did not use any opioid medication in the previous period, patients
using >4 opioid medications had higher odds of medication nonadherence. Other risk factors for
nonadherence included age <65>years, dual beneficiaries receiving low income subsidy, and higher
number of unique prescribers. Factors associated with lower odds of nonadherence included number of
different medications filled and >1 physician office visits in the previous period. When examining the
associations between medication nonadherence, and inpatient and ED use in Paper 2, we found that
among elderly Medicare beneficiaries, nonadherence was significantly associated with a 57% increase in
inpatient hospitalizations, and among non-elderly Medicare beneficiaries, nonadherence was significantly
associated with 41% increase in inpatient stays and 25% increase in ED visits. Similar associations were
found across all therapy classes examined (diabetes, cardiovascular, and COPD/asthma) in both age
groups. However, nonadherence to diabetes and COPD/asthma drugs was not significantly associated
with ED visits. Among other factors, mental illness, substance use disorder, non-Hispanic blacks and dual
low-income subsidy status were associated with higher inpatient and ED use. Finally, the DID analyses in
paper 3 showed that SafeMed Program did not improve medication adherence in vulnerable super-

utilizers with chronic conditions. However, for some sub-group populations including Medicare only
beneficiaries, patients >65 years of age, and patients with lower number of comorbidities, the intervention
may have ensured that the decline in the probability of being adherent was not as low as it would have
been in the absence of the intervention. Additionally, for patients diagnosed with COPD/asthma and
diabetes, there were positive medication use trends in favor of enrollees, however, these associations
were not statistically significant. CONCLUSIONS: This study is the first to our knowledge to demonstrate
the magnitude and importance of medication nonadherence in vulnerable super-utilizers with chronic
conditions. The study findings show that medication nonadherence is a significant problem among superutilizers with chronic conditions and is associated with high inpatient and ED utilization. Furthermore, the
findings suggest that medication management interventions during care transitions may not be sufficient
for these high-risk patients and other alternative strategies such as addressing social risk factors, and
removing cost barriers may be needed to improve adherence, especially among low-income dual
beneficiaries, Medicaid enrollees, and patients with higher comorbidity.
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ABSTRACT
BACKGROUND: Super-utilizers are individuals with disproportionately high inpatient
and emergency department (ED) use, and mostly have multiple chronic conditions and
use multiple concurrent medications. They place a substantial burden on the U.S.
healthcare system and have become the focus of policy initiatives aimed at reducing their
disproportionate inpatient and ED use. Medication management is critical for these
patients since nonadherence to essential chronic medications is associated with poor
health outcomes, and higher health care utilization and costs.
OBJECTIVES: This dissertation employed a three empirical research papers approach
to study the following aims: (1) the prevalence and patterns of medication nonadherence
to essential chronic medications in Medicare super-utilizers with chronic conditions, and
to identify the factors associated with medication nonadherence, with special emphasis on
factors including mental illness and use of opioid medications, (2) examine associations
between medication nonadherence, and inpatient and ED use, and to evaluate other risk
factors associated with health care utilization in Medicare super-utilizers with chronic
conditions, and (3) examine the impact of the SafeMed Program, a care transitions
program with a focus on medication management, on medication use and adherence
among publicly insured super-utilizers with chronic conditions.
METHODS: This dissertation was based on patients eligible for the SafeMed Program, a
care transitions program with a focus on medication management. The SafeMed Program
targeted publicly insured super-utilizers with chronic conditions who were admitted to
three hospitals that were part of a non-profit hospital system in Memphis, TN. The study
sample included Medicare or TennCare insured adults who met the SafeMed Program
eligibility criteria, had continuous medication coverage, and filled at least one of the drug
classes used to treat hypertension, congestive heart failure, coronary artery disease,
diabetes mellitus, chronic obstructive pulmonary disease (COPD), or asthma. Papers 1
and 2 were retrospective panel data analyses of the 2-year baseline data for Medicare Part
D beneficiaries meeting the SafeMed Program eligibility criteria. Association between
various factors and medication nonadherence was examined using random effects models
with a binary distribution. Association between medication nonadherence and inpatient
and ED utilization was examined using fixed effects negative binomial analyses. Paper 3
used a prospective quasi-experimental study design to examine the effectiveness of the
SafeMed Program on medication use and adherence among SafeMed participants
compared with patients in a control group using a difference in differences (DID)
approach.
RESULTS: Paper 1 demonstrated that the proportion of patients who were nonadherent
to their essential chronic disease medications ranged from 45.7% to 58.4%, with the
highest rate for COPD/Asthma medications (54.3% to 64.4%). In the multivariate
analysis examining predictors of medication nonadherence, we found that compared with
patients who did not use any opioid medication in the previous period, patients using >4
opioid medications had higher odds of medication nonadherence. Other risk factors for
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nonadherence included age <65 years, dual beneficiaries receiving low income subsidy,
and higher number of unique prescribers. Factors associated with lower odds of
nonadherence included number of different medications filled and >1 physician office
visits in the previous period.
When examining the associations between medication nonadherence, and inpatient and
ED use in Paper 2, we found that among elderly Medicare beneficiaries, nonadherence
was significantly associated with a 57% increase in inpatient hospitalizations, and among
non-elderly Medicare beneficiaries, nonadherence was significantly associated with 41%
increase in inpatient stays and 25% increase in ED visits. Similar associations were found
across all therapy classes examined (diabetes, cardiovascular, and COPD/asthma) in both
age groups. However, nonadherence to diabetes and COPD/asthma drugs was not
significantly associated with ED visits. Among other factors, mental illness, substance
use disorder, non-Hispanic blacks and dual low-income subsidy status were associated
with higher inpatient and ED use.
Finally, the DID analyses in paper 3 showed that SafeMed Program did not improve
medication adherence in vulnerable super-utilizers with chronic conditions. However, for
some sub-group populations including Medicare only beneficiaries, patients >65 years of
age, and patients with lower number of comorbidities, the intervention may have ensured
that the decline in the probability of being adherent was not as low as it would have been
in the absence of the intervention. Additionally, for patients diagnosed with
COPD/asthma and diabetes, there were positive medication use trends in favor of
enrollees, however, these associations were not statistically significant.
CONCLUSIONS: This study is the first to our knowledge to demonstrate the magnitude
and importance of medication nonadherence in vulnerable super-utilizers with chronic
conditions. The study findings show that medication nonadherence is a significant
problem among super-utilizers with chronic conditions and is associated with high
inpatient and ED utilization. Furthermore, the findings suggest that medication
management interventions during care transitions may not be sufficient for these highrisk patients and other alternative strategies such as addressing social risk factors, and
removing cost barriers may be needed to improve adherence, especially among lowincome dual beneficiaries, Medicaid enrollees, and patients with higher comorbidity.
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CHAPTER 1.

INTRODUCTION

MEDICATION ADHERENCE
Medication adherence has been defined as the active, voluntary, and collaborative
involvement of the patient in a mutually acceptable course of behavior to produce a
therapeutic result.1 It usually refers to the extent to which patients take medications as
prescribed by their health care provider.2 This form of patient behavior comprises of two
main concepts—adherence and persistence. Adherence refers to the intensity of the
therapy, whereas persistence refers to the overall duration of the therapy.1 Consistent and
long-term use of essential chronic disease medications is critical for the treatment of
chronic conditions such as diabetes, hypertension, cardiovascular disease (CVD), and
chronic lung disease. Nonadherence to essential medications is a major barrier to
achieving optimal therapeutic goals and is associated with poor clinical outcomes, and
higher health care utilization and costs.3-6 Studies have shown that poor adherence to
pharmacotherapy contributes to 33% to 69% of all medication-related hospitalizations
and leads to expenses of approximately $100 billion a year.7 Given the magnitude and
importance of medication adherence, assessing adherence has become an essential
component for clinical trials. Additionally, the National Committee for Quality
Assurance and Centers for Medicare and Medicaid Services (CMS) have included
medication adherence as a quality measure to evaluate healthcare plans.8
Medication nonadherence is a significant problem during the vulnerable period of
care transitions, especially among patients with multiple chronic conditions (MCC) and
complex medication regimen.9,10 There are two forms of nonadherence that may occur,
primary nonadherence and secondary nonadherence. Primary nonadherence is defined as
patient’s delay or failure to fill a new prescription, while secondary nonadherence—a
more widely studied phenomenon—is defined as filling a prescription but not taking it as
directed by the physicians.11 Research has shown that nearly 22% of prescription
medications are never filled11 and approximately 50% of all prescription medications for
chronic disease are not taken as directed by the provider.12 In the past, assessing primary
nonadherence was difficult because it required cumbersome review of office notes and
paper prescriptions. However, the recent increase in electronic prescribing systems has
enabled researchers to assess primary nonadherence by linking patient’s prescription data
with the pharmacy fill data. Secondary nonadherence, on the other hand, has been widely
studied by researchers and can be captured by most of the adherence measures including
patient-reported questionnaires or pharmacy administrative claims data. Studies
examining primary and secondary nonadherence after hospital discharge have mainly
focused on new medication users or patients who received new prescriptions during
hospital discharge.
A substantial body of evidence suggests that patients belonging to low
socioeconomic strata are particularly at a higher risk for primary nonadherence.11,13,14
Fisher and colleagues found that patients residing in low-income ZIP code areas were
more likely to not fill their new prescriptions.11 Additionally, in our previous study we
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found that more than 50% of vulnerable patients with MCC and polypharmacy (taking
multiple medications concurrently for disease management), and those residing in
medically underserved area, did not have all essential chronic and acute medications
within three days of hospital discharge.13 In another study by Kripalani and colleagues,
who evaluated medication reconciliation problems among inner-city patients after
hospital discharge, found that only 40% patients filled their medications on the day of
their discharge, 20% filled them within 1-2 days, 18% waited for 3-9 days, and 22% did
not fill them until 12 days after discharge.14 These studies highlight the importance of
examining primary nonadherence to essential chronic and acute medications in
vulnerable low-income populations and addressing any financial barriers which may be
playing a role in their non-adherent behavior.
Studies examining secondary nonadherence have found that the rates of adherence
drop progressively after hospital discharge. Newby and colleagues found that only 21%
of patients with coronary artery disease were adherent to all essential cardiovascular
medications over a 6-month period after hospital discharge.15 Ho and colleagues found
that among patients discharged with aspirin, β-blockers, and statins, nearly 34% of
patients stopped taking at least one medication and 12% stopped taking all three
medications within one month of discharge.16 Along with the issue of medication
nonadherence, vulnerable patients with MCC and those experiencing frequent transitions
of care are at far greater risk for drug therapy problems and adverse drug events (ADE).
Following hospital discharge, nearly 81% of the hospitalized patients experience drug
therapy problems,13 14% to 75% of patients experience medication discrepancies,13,17,18
and 11% to 30% of patients experience ADE of which about half are considered
preventable or ameliorable.19,20 Taken together, these study findings suggest that
medication management is critical during the vulnerable period of care transitions,
especially among patients who are at risk of drug therapy problems and medication
nonadherence.
Methods to Measure Adherence
There are several ways to measure adherence, which have been broadly classified
as direct and indirect measures of adherence. Direct methods include directly observed
therapy, measuring drug or metabolite concentration in body fluids, or measuring of
biological markers in the blood that has been added to the drug formulation. Indirect
measures of adherence include patient questionnaires and self-reports, pill counts, rates of
prescription refills, electronic medication monitors, measuring physiologic markers, and
asking patients to maintain diaries. The advantage of using direct methods is that it is
possible to assess directly whether the patient has consumed medications or not, or
whether the correct dose of medication has been taken or not. With indirect methods that
assess adherence using patient responses or analyzing their pharmacy claims data, it is
not possible to know whether the patient adheres to the agreed upon dosage and timing of
the medication regimen. The choice of the adherence measure depends on the availability
of the data and cost. Although direct methods have been considered more reliable and

2

accurate than indirect methods, these methods are expensive, tedious, and not practical
for routine clinical use.7,21
Among indirect methods, patient questionnaires such as Morisky medication
adherence scale has been used in many studies and has produced reliable results for
patients with hypertension and diabetes;22 however, the accuracy and validity of this
method remains uncertain in patients with multiple chronic conditions using multiple
concurrent medications.13 Adherence to Refills and Medication Scale (ARMS) is another
patient-reported measure that can be used for chronic disease population and is a reliable
medication adherence scale for patients with low literacy.23 However, the drawback of
using most patient-reported adherence measures is that they provide a subjective way to
measure adherence and patients may obfuscate and provide desired answers, and also
subject to recall bias. Additionally, patient-reported adherence measures are susceptible
to misrepresentation by the person collecting the data. Measuring adherence using
pharmacy administrative data has gained importance recently and has become one of the
most commonly used methods in the literature. Availability of pharmacy administrative
data has enhanced our ability to measure adherence by understanding patients’
prescription refill patterns and behaviors that are necessary to achieve desirable treatment
outcomes. Moreover, this method provides an objective method to assess adherence.
Using this method, most observational studies and randomized clinical trials use a
standard cut-off value of 80% and classify patients as adherent if they have medications
on hand available for at least 80% of the total duration of time.1 Moreover, studies have
established the clinical significance of defining the optimal adherence threshold of 80%
or above.1,7
Rates of refilling prescriptions is an accurate method to measure adherence in a
closed pharmacy system (e.g., continuous Medicare Part D enrollment). However, the
disadvantages of using this method are that it cannot capture primary nonadherence and
may not accurately capture medication use beyond the medication fill. Additionally,
pharmacy administrative claims data is widely used to assess adherence for a single drug
class. However, measuring adherence for patients with MCC is difficult since patients use
multiple concurrent medications. Choudhry and colleagues conducted a study to propose
methods for measuring adherence to multiple medications.21 The study found variations
in adherent rates depending on the way adherence was defined. And the study concluded
that the choice of method depends on the reason why adherence is being measured. The
interval-based proportion of days covered (PDC) is one of the standardized methods
proposed in this study to measure adherence to concurrent medications. The intervalbased PDC is defined as medication possession during the interval from the index date to
the end of the period, that is, number of days of medication supplied throughout the
period (numerator) divided by number of days in the period (denominator). This method
can be applied in following three distinct ways: 1) measuring average PDC for each
patient based on the number of drug classes used by the patient, 2) measuring number of
days during the period in which patients had at least one of the prescribed medications for
a chronic condition, and 3) examining whether patients had a PDC of 80% or more for
each medication they were using for a chronic condition. Different methods produce
varying adherence estimates, and measuring average PDC (method #1) seems more
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reliable since it produces intermediate adherence estimates when compared with the other
two methods. Requiring patients to have a PDC of >80% for all medications may
categories more patients as nonadherent, while requiring patients to be adherent to at least
one or their medications may categorize more patients are adherent.21
Barriers to Medication Adherence
Barriers to medication adherence are multifactorial. The World Health
Organization (WHO) has classified barriers to medication adherence into five broad
categories: 1) patient-related factors, 2) patient conditions, 3) therapy related factors, 4)
socioeconomic factors, and 5) health system related factors.1 Patient factors include age,
gender, and race and ethnicity (minority race in particular). Patient conditions that are
chronic in nature and require long-term therapy have been found to be associated with
nonadherence. For therapy-related factors, patients having polypharmacy and complex
therapy or patients experiencing side effects are more likely to have poor adherence.
Among socioeconomic factors, lower education level, low income, and low health
literacy are major barriers. Health system factors also play an important role in
medication nonadherence. Some of the health care system-related barriers include having
high cost of medications, copays, restricted formularies, or switching to another
formulary.
Review of existing literature demonstrates that the most important factors
associated with medication nonadherence include young age, black race, medication
copay, mental illness, multiple comorbidities, and therapy complexity, among others.3,7,2429
System-level factors such as inadequate post-discharge treatment plan, lack of patient
counseling, discharge summaries lacking discharge medications, and failure to monitor
patient’s drug therapy are associated with nonadherence and other drug therapy problems
during care transitions.18-20,30-34 Makaryus and colleagues found that less than 50% of
patients were able to list their discharge medications and even fewer could recount their
purpose.35 In our previous study, we found that drug therapy problems and post-discharge
medication discrepancies were common among super-utilizing patients with MCC and
polypharmacy. The major causes of medication discrepancies were higher number of
comorbidities, difficulty in picking up and paying for medications, and transportation.13
Additionally, Kripalani and colleagues found that medication costs and transportation
served as major barriers to proper medication use after hospital discharge among innercity patients.14 A comprehensive patient-centered approach addressing contributors to
medication nonadherence and other drug therapy problems both at the patient- and
system-level is needed to target effective interventions for vulnerable populations.
Association of Adherence with Health Outcomes and Costs
Studies have demonstrated the positive impact of appropriate adherence on
clinical outcomes. For instance, Bailey and colleagues found that among TennCare
beneficiaries, a 15% increase in antihypertensive medication refill adherence was
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associated with an 8% decreased hazard of stroke and a 7% decreased hazards of death.3
Ho and colleagues conducted a retrospective cohort study of patients with diabetes and
found that nonadherent patients had significantly increased risk for all-cause
hospitalization and all-cause mortality.36 Another observational study by Ho and
colleagues among a cohort of patients with coronary artery disease showed that
nonadherence to cardioprotective medications (beta blockers, statins, and/or angiotensinconverting enzyme inhibitors) was associated with increased risks for cardiovascular
mortality and cardiovascular hospitalization.37
Studies have also demonstrated the impact of medication adherence on health care
utilization and costs. Sokol and colleagues analyzed a cohort of patients with four chronic
conditions (diabetes, hypertension, hypercholesterolemia, and congestive heart failure)
and found that high medication adherence was significantly associated with lower
hospitalization and lower non-medication medical costs, yielding a net reduction in the
overall healthcare costs.38 Roebuck and colleagues evaluated patients with congestive
heart failure, hypertension, diabetes, and dyslipidemia and found that although improved
medication adherence increased pharmacy costs, it also produced substantial medical
savings by reducing hospitalizations and emergency department (ED) use.5 Jha and
colleagues examined a national sample of diabetes patients and found that improved
adherence to diabetes medications was associated with lower hospitalization and ED
visits. Furthermore, the study projected that improved adherence to diabetes medications
could avert 699,000 ED visits and 341,000 hospitalizations annually, generating savings
of $4.7 billion.4 Similar findings were observed by studies conducted on Medicare
beneficiaries. Simoni-Wastila and colleagues found that Medicare patients with chronic
obstructive pulmonary disease (COPD) who were adherent to their chronic medications
experienced fewer hospitalizations.6 And in a sample of Medicare patients with
myocardial infarction, Zhang and colleagues found that higher adherence with βblockers, statins, and ACEIs/ARBs medications was associated with lower readmission
rates.39 Findings from these studies reinforce the importance of taking medications as
prescribed by the provider to optimize patient health outcomes and reduce health care
utilization and costs. Previous studies based on Medicare population examining the
association between medication adherence and utilization were largely represented by
elderly Medicare beneficiaries and did not target vulnerable patients with high rates of
multimorbidity and high health care utilization.
Interventions to Improve Adherence
Multimodal interventions focusing on multiple barriers of medication adherence
have mostly shown improvements in medication adherence and reduced health care
utilization. For instance, the Ashville projects that combined expanded medication
therapy management (MTM) and disease management services, showed improved
clinical outcomes and reduced overall costs in studies targeting commercially insured
patients with diabetes, hypertension/dyslipidemia, or asthma.40-42 Similarly, Pringle and
colleagues evaluated the impact of a large-scale, pharmacy-based intervention on five
chronic medication classes and found that, compared to the control group, the
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intervention group had improved adherence for all medication classes.43 Zillich and
colleagues evaluated the effect of a program combining specialized medication packaging
and phone MTM on medication adherence, health care utilization, and costs, among
Medicaid patients. The study findings showed a significant improvement in medication
adherence in the program cohort compared to controls; however, the effect on health care
utilization and health care costs did not vary between the two groups.44 Additionally,
Martin and colleagues examined the effectiveness of community-based, multimedia
interventions on medication adherence among low-income rural residents with
hypertension and found that medication adherence did not differ significantly from
individuals in the control group.45
INTEREST AND EVIDENCE IN CARE TRANSITIONS
Care transitions is described as a process when patient’s care shifts from being
provided in one setting to another, for instance moving from a hospital to a patient’s
home.46 Patients with complex care needs often require care at different settings. During
care transitions, these patients often experience difficulties in managing their care and
face problems of care fragmentation. Managing care transitions is important since
inadequate management contributes to $25 to $45 billion in wasteful spending mainly
through avoidable complications and unnecessary health care utilization.46 The famous
report by the Institute of Medicine, Crossing the Quality Chasm, highlighted this issue
and reported that upon hospital discharge, patients receive little information on selfmanagement and medication side effects causing unnecessary readmissions. For instance,
75% of the hospital readmissions among Medicare population are considered potentially
preventable, resulting in $12 billion in unnecessary Medicare spending each year.46
Several care transitions models have been developed and evaluated. The Care
Transitions Intervention developed by Eric Coleman utilized nurses and social workers to
promote development of patient’s skills in four key self-care areas including managing
medications, timely follow-up care, identifying and responding to ‘red-flags’ (onset of a
fever or worsening of a condition), and having a patient-centered record owned by the
patient to simplify information transfer. The program evaluation demonstrated a 30%
reduction in 30-day hospital readmissions, 17% reduction in 180-day hospital
readmission, and reduced average cost per patient by 17%. Another care transitions
model that has been evaluated is the Naylor model developed by Mary Naylor and
colleagues. The intervention targeted high-risk, high-cost elderly patients and was
provided for a longer period. The program evaluation reduced readmissions by 36% and
costs by 39% per patient during 12 months following hospitalization. This program not
only provided interventions in the hospital setting but also extended it to the community
setting by incorporating regular home visits. However, care transitions models developed
so far have not primarily focused on identifying and resolving medication-related issues
during care transitions. There is a lack of evidence regarding the effectiveness of
medication management interventions during care transitions, especially among
vulnerable high-risk patients with chronic conditions and polypharmacy.
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INTERVENTIONS IMPACTING MEDICATION MANAGEMENT DURING
CARE TRANSITIONS
Given the increased interest in care transitions and widespread recognition that
drug therapy problems and medication nonadherence play a major role in readmissions,
care transitions interventions with a focus on medication management are being
increasingly explored to reduce drug therapy problems and improve medication
adherence. Pharmacists can play a central role in care transitions models focused on
medication management. Pharmacist-led care transitions interventions that have focused
on comprehensive discharge planning with an emphasis medication reconciliation and
phone follow-ups have generally been successful in identifying drug therapy problems
and reducing disease exacerbations and hospitalizations.17,47-52 For instance, in our prior
study based on SafeMed participants with MCC, polypharmacy, and high health care
utilization, we found that the Pharmacist-led interventions as part of a care transitions
program successfully resolved 50% of patients’ medication-related issues, resulting in
substantial estimated cost savings.13 Schnipper and colleagues found that pharmacistprovided interventions for patients discharged home from the general medicine service
was associated with a lower rate of preventable ADE. However, there was no significant
effect of these interventions on overall ADE or total health care utilization.17 Similarly,
Ho and colleagues found that among patients with acute coronary syndrome, multifaceted
pharmacist-led interventions increased adherence to cardioprotective agents one year
following hospital discharge. However, the intervention did not have any positive effect
on blood pressure and low-density lipoprotein cholesterol levels.49 A review of studies by
Kaboli and colleagues examining the effects of pharmacist interventions on processes and
outcomes in hospitalized adults, demonstrated improvement in quality, safety, and
efficiency of care.53 In a sample of patients discharged from the hospital to the nursing
home, Boockvar and colleagues found that pharmacist-conducted medication
reconciliation and care coordination with physicians reduced medication discrepancies in
these patients.52 Similarly, Dudas and colleagues found that among patients discharged
from hospital to home, pharmacist-facilitated discharge process was associated with
increased patient satisfaction, resolution of medication-related problems and lower ED
visits.50 And in another study by Phatak and colleagues conducted on patients using highrisk medications or multiple medications, the pharmacist services provided during care
transitions reduced readmissions and ED visits.51
There are few studies which did not find any positive effect of care transitions
based pharmacist-provided medication management interventions. For instance,
Kripalani and colleagues found that among patients hospitalized with acute coronary
syndromes or acute decompensated heart failure, the hospital-based pharmacist-led
interventions did not significantly reduce medication errors after hospital discharge.19
Additionally, Walker and colleagues found that pharmacist intervention during hospital
discharge did not significantly reduce readmissions or ED visits in patients who were at
high risk for medication-related adverse events.54 Although most studies described above
have shown positive effects of medication management interventions provided during
care transitions, its effectiveness in vulnerable patient populations with chronic
conditions and among those experiencing frequent hospitalizations remains unclear.
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SUPER-UTILIZERS
Super-utilizing patients are those who have high health care costs from recurring,
preventable inpatient or ED visits. They often face complex medical and social issues55
and are particularly at risk for drug therapy problems and medication nonadherence
during care transitions from hospital to the community setting.13,18 A decade ago Dr.
Jeffrey Brenner, a physician from Camden, NJ, had identified that a small group of
patients accounted for a bulk of health care costs.55 Since then the interest in superutilizers has increased among policymakers, health systems, and researchers. Superutilizers represent only 3 to 10% of Medicare and Medicaid population, but are
responsible for 30 to 50% of the health care spending.56 They often face complex medical
and social issues including mental health illnesses and substance abuse and frequently
report chronic pain.56-58 A previous study found that 82% of super-utilizers had MCC and
41% had a serious mental health diagnosis.56 Another study found that nearly 46%
patients reported not having a regular primary care provider, and nearly 48% reported
having severe pain during hospitalization.57 Additionally, Medicaid super-utilizers are
more likely to have comorbid conditions, behavioral health, and substance abuse
conditions when compared to Medicare super-utilizers. A study found that among top
high spending Medicaid super-utilizers, nearly 83% had >3 chronic conditions and about
60% had >5 conditions.56,59 Because of frequent transitions of care, super-utilizers are at
high risk for drug therapy problems and medication discrepancies which may cause poor
adherence. Thus, medication management is critical among high-risk super-utilizing
patients to achieving optimal therapeutic goals. Despite increased focus on reducing the
disproportionate health care utilization and costs among super-utilizer, there are very few
published studies examining these outcomes among the vulnerable super-utilizing patient
population. And, to our knowledge, no study has focused on the issue of medication
nonadherence in the super-utilizing population.
SAFEMED PROGRAM: A CARE TRANSITIONS PROGRAM WITH A FOCUS
ON MEDICATION MANAGEMENT
The SafeMed Program was a Centers for Medicare and Medicaid Services (CMS)
Health Care Innovations Award (HCIA) funded care transitions program with a focus on
medication management.60 The program included comprehensive targeted interventions
to improve adherence to safe and effective medications among publicly insured
(Medicare, Medicaid, or dually eligible), super-utilizers who were admitted to three
hospitals that were part of a non-profit hospital system in Memphis, TN from February 1,
2013 to May 1, 2015. The program enrollment occurred during an inpatient admission or
an observation stay, after which the patients agreeing to participate were provided the
various intervention services for a minimum of 45 days. A diverse team of health care
providers, including pharmacists, pharmacy technicians, and nurse practitioners, among
others, worked in collaboration with physicians to prevent, identify, and resolve any
drug-related issues, which may lead to low medication adherence and suboptimal
medication therapy.
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Pharmacists along with pharmacy technicians worked together to improve the
care transitions process of patients from the inpatient hospital setting to the community
setting by providing medication management services. Pharmacist-led interventions as
part of the SafeMed Program included: comprehensive medication review (CMR),
targeted medication therapy management (MTM), enhanced discharge planning, home
visits, phone follow-ups, medication reconciliation during discharge and post-discharge,
and care coordination with patient’s physicians. The SafeMed model differs from earlier
care transitions models by focusing explicitly on high risk super-utilizers of inpatient and
emergency services rather than all hospitalized patients targeted by hospital-focused care
transitions models such as Project Boost,61 the Bridge Program,62 and Project RED.63
And unlike other super-utilizer focused care transitions models such as the Camden
Coalition,64 the Coleman Care Transitions Program,9,65 and the Naylor Transitional Care
Model,66 SafeMed focused on proven medication therapy management
approaches19,42 using program pharmacists and pharmacy technicians as key team
members.
CONCEPTUAL FRAMEWORK
The present study uses the Andersen's Behavioral Model of Health Services
Utilization to demonstrate associations between risk factors, medication nonadherence,
and inpatient and ED utilization. This model defines the utilization of health services as a
function of (1) predisposing, (2) enabling, and (3) need factors.67 Predisposing factors
refer to the individual's characteristics that are present before the illness. These factors
include the demographic characteristics of age and sex, social factors including
occupation, education, ethnicity, and social relationships, and health beliefs (attitudes,
values, knowledge related to health services). Enabling characteristics refer to financing
and organizational factors. Financial factors include income and wealth that can be used
to pay for health services or health insurance status. Organizational factors refer to
whether an individual has a regular source of care and nature of that source. Health
policies also fall into the category of enabling factors. Need characteristics refer to a
patient's need to seek health care services. At an individual level, need factors can be
differentiated as perceived need for health services or evaluated need.
Although, this model was originally developed to predict health services
utilization, it has been used to predict medication adherence. For instance, Murray and
colleagues used this model to examine the associations between environmental factors,
patient characteristics (predisposing, enabling, and need factors), and medication
adherence to predict utilization outcomes.68 Another study by De Smet and colleagues
used Andersen’s Behavioral Model to examine self-reported adherence to asthma
medications and found that better adherence was associated with greater perceived
asthma severity, longer asthma duration, stronger beliefs in the benefits of treatment,
among others.69 The conceptual framework for this study is shown in Figure 1-1. In this
study, we propose that the predisposing, enabling, and need factors predict medication
nonadherence, and all these factors along with medication nonadherence predict inpatient
and ED utilization. In this study, the predisposing factors include age, gender, and race.
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Figure 1-1. Conceptual Framework Based on Anderson Behavioral Model of
Health Services Utilization
Modified with permission. Andersen RM. Revisiting the behavioral model and access to
medical care: does it matter? Journal of health and social behavior. Mar 1995;36(1):1-10.
Note: In our study the predisposing factors include age, gender, and race. The enabling
factors include dual low-income cost sharing subsidy status, ≥1 physician office visits,
number of unique prescribers, and number of unique pharmacies. The need factors
include Charlson comorbidity index, mental illness, tobacco use disorder, opioid
medications filled, and number of unique medications filled.
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The enabling factors include dual low-income cost sharing subsidy status, >1 physician
office visits, number of unique prescribers, and number of unique pharmacies. The need
factors include Charlson comorbidity index, mental illness, tobacco use disorder, opioid
medications filled, and number of unique medications filled.
STUDY SIGNIFICANCE
With the implementation of Hospital Readmissions Reduction Program by the
Affordable Care Act (ACA), hospitals are being penalized by Medicare for readmissions
occurring within a month of discharge for conditions including acute myocardial
infarction and heart failure. This has spurred interest in super-utilizers populations.
Super-utilizers place a substantial burden on the healthcare system and have become the
focus of policy initiatives aimed at reducing their disproportionate inpatient and ED
visits. Hospitals and payers are important stakeholders interested in reducing avoidable
use of inpatient and ED services among high-risk super-utilizers. Many care transitions
models are increasingly explored, with varying target populations and focusing on
different risk factors causing avoidable readmissions and ED use. Medication
management is a critical component for these high-risk patients since they are at high risk
for drug therapy problems and medication discrepancies, which may result in poor
adherence and thereby result in high health care utilization and costs. Given the clinical
importance of medication nonadherence, it is imperative to understand the magnitude of
this issue in super-utilizers with chronic conditions.
Numerous studies have examined the risk factors for medication nonadherence in
different populations and its association with health care utilization, however, to our
knowledge, such associations have not been established in vulnerable super-utilizers with
chronic conditions. Additionally, given the increased focus on reducing the
disproportionate inpatient and ED use in this patient population, it is important to
understand whether nonadherence to essential chronic medications contributes to their
high inpatient and ED use. Moreover, considering the high prevalence of mental illness
and chronic pain in the high-risk super-utilizing population, it is critical to examine
whether mental illness and opioid medication use are associated with nonadherence and
health care utilizations in this vulnerable population. Finally, demonstrating the impact of
an innovative care transitions program on medication adherence will be critical in
highlighting the central importance of medication management in improving transitions
of care—that care transitions programs focusing on medication management can improve
medication use and adherence among vulnerable super-utilizers who can benefit the most
from such interventions. The study findings may facilitate the adoption of such care
transitions programs that are targeted towards vulnerable populations and may have the
potential to impact changes in the future health care delivery, to move in the direction of
a more patient-centered care transitions program with a focus on medication
management.
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RESEARCH AIMS
Using Medicare and Tennessee Medicaid data on super-utilizers with chronic
conditions, this dissertation aims to investigate the predictors of medication
nonadherence, association between nonadherence and high inpatient and ED utilization,
and the impact of the SafeMed Program on medication use and adherence.
Aim 1
To examine the prevalence and patterns of medication nonadherence to essential
chronic medications, and factors associated with medication nonadherence, with special
emphasis on factors including mental illness and use of opioid medications
Are demographic, socioeconomic, clinical, therapy complexity, and physician
office visits associated with overall nonadherence to essential chronic
medications?
Are mental illness and opioid medication use associated with overall
nonadherence to chronic essential medications?
Aim 2
To examine the associations between medication nonadherence, inpatient and
emergency department use. Additionally, to examine if other risk factors including
mental illness and opioid medication use, are associated with inpatient and ED use
Hypothesis 2a: Medication nonadherence to essential chronic medications (overall
and therapy specific nonadherence) is associated with high inpatient and ED use
in Medicare beneficiaries <65 years of age
Hypothesis 2b: Medication nonadherence to essential chronic medications (overall
and therapy specific nonadherence) is associated with high inpatient and ED visits
in Medicare beneficiaries >65 years of age
Are mental illness, opioid medication use, and other factors associated with high
inpatient and emergency department use?
Aim 3
To examine the impact of the SafeMed Program on medication use and
medication adherence
Hypothesis 3a: SafeMed Program is associated with an increase in medication
adherence (overall and therapy specific adherence) among the treatment group
compared to the control group
Hypothesis 3b: SafeMed Program is associated with an increase in condition-
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specific medication utilization in the treatment group compared to the control
group
Hypothesis 3c: Does the impact of SafeMed Program on medication adherence
vary by age, type of public health insurance, and number of comorbidities?
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CHAPTER 2. PREDICTORS OF MEDICATION NONADHERENCE IN
SUPER-UTILIZERS WITH CHRONIC CONDITIONS
BACKGROUND
The disproportionately high health care utilization and resulting colossal
Medicare spending among a small fraction of Medicare beneficiaries is well
established.56,70,71 Nearly 50% of the health care spending is incurred by 5% of the
Medicare population.58 These high-cost health care users are commonly referred to as
“super-utilizers”.71 They often have complex health and social issues and have high rates
of multiple chronic conditions (MCC) including mental health disorders.56,58 Substantial
research shows that patients with MCC and polypharmacy are at high risk of medication
nonadherence. The therapeutic regimen for patients with MCC is complex, often
involving multiple concurrent medications, which puts them at greater risk of drug-drug
interactions and makes these patients less likely to be adherent to their therapy.72-74 In
addition, patients who experience frequent transitions of care are particularly at higher
risk of drug therapy problems and medication discrepancies, which may contribute to low
medication adherence. For instance, after hospital discharge nearly 14% to 75% of
patients experience medication discrepancies,13,17,18 11% experience adverse drug events
(ADE),20 and 23% to 48% do not take their medications as directed.14,17 Medication
management is critical for super-utilizing patients since nonadherence to medications is
associated with poor health outcomes, and higher hospital admissions and costs.5,38
The World Health Organization has reported that nearly 50% of patients in
developed countries do not take their medications as directed by physicians.12 The
reasons for medication nonadherence are multifactorial, including patient, condition,
therapy-related, socioeconomic, and health system-related factors.1 Review of existing
literature demonstrates that the most important factors associated medication
nonadherence include young age, black race, medication copay, mental illness, multiple
comorbidities, and therapy complexity, among others.3,7,24-29 However, to our knowledge
no research has examined the factors associated with medication nonadherence among
super-utilizers with chronic conditions. Moreover, emerging evidence on super-utilizers
indicates they have a high prevalence of mental illness and substance use disorder, and
frequently report chronic pain.56,57,75 For instance, Johnson and colleagues found that
among publicly insured and uninsured super-utilizers, nearly 41% had a serious mental
health diagnosis.56 In another study conducted on super-utilizers, Harris and colleagues
found that nearly 48% of patients reported severe pain (>7 on a 10-point scale).57
Considering the high prevalence of severe pain in super-utilizing patients, we anticipate
that the use of opioid medications would be high in this population. Therefore, it is
imperative to examine whether factors such as mental illness and opioid medication use
are associated with medication nonadherence in this high-risk population.
Therefore, this study examines, using Medicare administrative claims data, the
prevalence and patterns of medication nonadherence to essential chronic medications in
super-utilizers with chronic conditions, and the factors associated with medication
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nonadherence, with special emphasis on factors including mental illness and use of
opioid medications.
METHODS
Design and Setting
SafeMed Program is a Centers for Medicare and Medicaid Services (CMS) Health
Care Innovations Award funded care transitions program with a focus on medication
management.76 The SafeMed Program targeted super-utilizers between February 2013
and May 2015 who were admitted to three hospitals that were part of a non-profit
hospital system in Memphis, TN. The present study is a retrospective panel analysis of
the 2-year baseline data for Medicare Part D beneficiaries meeting the SafeMed Program
eligibility criteria during the enrollment period from February 2013 to December 2014.
The study used Medicare beneficiary eligibility, inpatient, outpatient, professional, and
Part D event files data to document the sociodemographic, clinical, therapy complexity,
and health services utilization factors associated with medication nonadherence. This
study included SafeMed eligible patients because they were diagnosed with chronic
conditions (hypertension, diabetes mellitus, congestive heart failure (CHF), coronary
artery disease (CAD), chronic obstructive pulmonary disease (COPD), or asthma) that
have been identified as ambulatory care-sensitive conditions for which outpatient care
improvements such as improving medication adherence, can reduce inpatient
utilization.57 Since medication adherence is a dynamic process that changes over time, the
two-year data for each patient was divided into four 6-month patient-periods. The panel
design helped us to examine patterns of medication nonadherence in the baseline period
before the intervention, and the association of time-varying and time-invariant factors
with medication nonadherence among Medicare super-utilizers.
Study Population
The study included Medicare beneficiaries who were deemed eligible for the
SafeMed Program during a portion of the enrollment period between February 2013 and
December 2014. The SafeMed Program eligibility was determined during an inpatient
admission or an observation stay (index admission). SafeMed Program eligibility was
based on the following inclusion criteria: 1) adults aged 18 years or older with continuous
Medicare enrollment, 2) >2 hospital admissions in the past six months OR 1 hospital
admission and >2 emegerncy department (ED) visits in the six months prior to the index
admission, and 3) diagnosis of >1 of the following chronic conditions: hypertension,
CHF, CAD, diabetes mellitus, asthma, or COPD. The International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM codes] for the chronic
conditions are listed in Appendix A, Table A-1.
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Patients were excluded from the SafeMed Program if the primary reason for index
admission was related to cancer, pregnancy, or a surgical procedure for an acute problem
following the approach of Jencks and colleagues recognizing that health care utilization
for these conditions is less likely to be affected by outpatient chronic disease care or
medication management.77 Patients were also excluded if they had diagnoses of active
psychosis, drug abuse, substance abuse or suicidal ideation during the index admission,
or if they were discharged to a skilled nursing facility or hospice care because of
evidence suggesting that these patient populations may be less amenable to outpatient
intervention.57 The ICD-9-CM codes and diagnosis-related group (DRG) codes for the
exclusion criteria are listed in a previous paper by Harris and colleagues.57
Of the 1,714 Medicare patients meeting SafeMed inclusion and exclusion criteria
above, the final sample included the 1,092 (63.7%) who were continuously eligible for
Medicare Part D during the 2-year evaluation period and who had filled at least one of the
seventeen drug classes during the 2-year baseline evaluation period. These drug classes
included angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor
blockers (ARB), statins, antiplatelet agents, beta-blockers, calcium channel blockers,
diuretics, alpha-1 blockers, central alpha-2 agonists, direct vasodilators, sulfonylureas,
biguanides, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors,
anticholinergic inhalers, inhaled corticosteroids alone or in combination with long-acting
beta-agonists (LABA), and other COPD/asthma medications (theophylline and
leukotriene modifiers).
Study Outcomes
The study’s outcome was repeated measures of medication nonadherence
measured as interval-based proportion of days covered (PDC).21 PDC was measured
based on total number of days supplied for each drug class divided by the observation
time interval for each 6-month period. Drugs that belonged to the same therapeutic class
(example, amlodipine, and nifedipine in the calcium channel blockers) were considered
interchangeable. Additionally, based on the evidence-based guideline, ACE inhibitors
and ARB were considered a single class for this study.78 Antiplatelet agents did not
include aspirin because aspirin is usually purchased without a prescription (over-thecounter) and are not included in Part D claims data. Moreover, we did not include insulin
since the days’ supply information on this drug class is not accurate.79 Interval-based
PDC was measured if patients had >2 medication fills for any of the seventeen drug
classes during a 6-month period. Using this approach, the numerator was defined as the
number of days of medication supplied between the first and last prescription in a period
and the denominator was defined as the number of days during the interval from the
index date, which was the first day of the medication fill in a 6-month period, to the last
day of that period. The average PDC measure was calculated at the patient-level by
adding the PDC for each drug class and then dividing by the number of drug class used
by the patient. Patients were then classified as nonadherent if they had PDC<80% over
the 6-month period. Adherence was also measured based on therapy-specific medication
adherence classifications, which included diabetes, cardiovascular, and COPD/asthma
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medications. Additionally, as a sensitivity analysis, we measured adherence by changing
the fill criteria of >2 medication fills for a drug class to >1 medication fill.
Recognizing that the above definition for measuring PDC might overestimate
adherence, another sensitivity analysis was conducted using an alternative PDC
definition—patients were followed continuously from the time they had >2 fills during a
6-month period for a drug class, to the last 6-month period. We modified the denominator
by using the first day of medication fill as index date only if patients had >2 fills for a
drug class for the first time in a period. If patients filled >2 medications for a drug class
in the previous period, we considered the denominator as 180 days. Additionally, we
subtracted the inpatient days from the denominator. For the numerator, if the days’
supply extended into the next period, it contributed to both periods.
Independent Variables
Sociodemographic variables were assessed using Medicare eligibility and
prescription drug event files. Age, gender, and race/ethnicity were measured at baseline.
Other sociodemographic factors measured for each 6-month period included whether
patients were fully or partially eligible as dual beneficiaries in >1 months and whether
patients received low-income cost sharing subsidy (LICS) for the index drug classes. The
income threshold to be eligible for Tennessee Medicaid (TennCare) is 105% of the
federal poverty level (FPL), while the income threshold for receiving LICS is higher—
150% of the FPL. We combined these factors to create a variable with three groups (nondual non-LICS, non-dual LICS, and dual LICS).
Clinical factors that were assessed at baseline included information on whether
beneficiaries qualified for Medicare because of end-stage renal disease (ESRD) and
whether beneficiaries had any disability. Disability was not included in the bivariate and
multivariate models since everyone <65 years of age was also disabled. The ICD-9
diagnosis codes present on at least one Medicare inpatient, outpatient, or Part B claim
were used to identify patients in each 6-month period who had qualifying chronic
conditions or comorbidities. Overall comorbidity was measured using the University of
Manitoba SAS Macro for Charlson comorbidity index (mean).80 Additionally, the
SafeMed Program’s qualifying chronic conditions included: diabetes, hypertension, CHF,
CAD, COPD, and asthma. We only included Charlson comorbidity index in the bivariate
and multivariate models as a comorbidity measure, since it includes the qualifying
conditions and ESRD. In addition to this, we assessed mental illness (defined as a
diagnosis of depression or anxiety or >1 anxiolytic or antidepressant fills) and tobacco
use disorder. The ICD-9-CM codes for anxiety, depression, and tobacco use disorder are
listed in Appendix A, Table A-1.
Therapeutic complexity and health services utilization factors were assessed for
each 6-month period, using prescription drug event and Part B claims files. Therapeutic
complexity-related factors included the number of unique medications filled, opioid
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medications filled (0, 1, 2-3, or >4 fills), number of unique prescribers, and number of
unique pharmacies. Health services utilization factors included >1 physician office visits.
Statistical Analysis
Descriptive analyses were conducted to show the characteristics of super-utilizers
and medication nonadherence rates in each 6-month period. For bivariate and
multivariate analyses, we pooled observations from the four 6-month periods. The unit of
analysis for the bivariate and multivariate models was patient-period. Chi-square tests
and t-tests were conducted as part of the bivariate statistics. We used random effects
model with a binary distribution to obtain associations between independent variables
and medication nonadherence. The model included lagged effects of comorbidities,
therapy complexity, and physician office visits. As a subgroup analysis, we estimated
separate multivariate models for each age group (i.e., <65 and >65 years) to understand
associations specific to these Medicare age groups. Data cleaning was performed using
SAS 9.4 and all data analyses were conducted using STATA 13. Variables in the
multivariate models with P<0.05 were considered significant.
RESULTS
Characteristics of the study population (N=1,092) in each 6-month evaluation
period is shown in Table 2-1. The mean age of the study population was 65.1 years, and,
43.0% were <65 years of age. The study population was predominantly female (58.8%),
non-Hispanic Black (68.6), dual eligible (63.7%), and received LICS (68.7%). In the
fourth period, patients had a mean of 3.1 inpatient stays and 1.7 ED visits. Additionally,
in the same period, 97.2% of the study patients had >2 chronic conditions, 57.0% were
diagnosed with depression/anxiety or had filled >1 antidepressants or anxiolytics, and
69.0% had filled >1 opioid medications. These proportions were higher in the fourth
period than previous periods.
Rates of nonadherence to essential chronic disease medications are shown in
Table 2-2. We found that 40.4% of patients were nonadherent to their diabetes
medications, 48.2% to their cardiovascular medications, and 54.3% to their
COPD/asthma medications. Nonadherence rates for cardiovascular and COPD/asthma
medications were higher in the fourth period than previous periods. When examining
overall nonadherence rate, we found that 45.7% of patients were nonadherent to their
essential chronic medications.
Main Analysis
Bivariate associations with medication nonadherence are shown in Table 2-3. In
the multivariate analysis (Table 2-4), we found that patients who filled >4 opioid
medications in the previous period had higher odds of medication nonadherence
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Table 2-1.

Characteristics of the Study Sample in Each 6-Month Patient-Period (N=1,092)
Characteristics

Period 1
N (%)

Period 2
N (%)

Period 3
N (%)

Period 4
N (%)

468 (42.9)
624 (57.1)
65.1 (14.5)
642 (58.8)

-

-

-

-

-

-

326 (29.9)
749 (68.6)
17 (1.6)

-

-

-

407 (37.3)
324 (29.7)
696 (63.7)
750 (68.7)

694 (63.6)
790 (72.3)

697 (63.8)
791 (72.4)

692 (63.4)
803 (73.5)

852 (78.0)
571 (52.3)
338 (31.0)
368 (33.7)
134 (12.3)
246 (22.7)

950 (87.0)
638 (58.4)
467 (42.8)
481 (44.1)
199 (18.2)
343 (31.4)

1,028 (94.1)
696 (63.7)
603 (55.2)
590 (54.0)
262 (24.0)
448 (41.0)

1086 (99.5)
784 (71.8)
799 (73.2)
785 (71.9)
377 (34.5)
583 (53.4)

335 (30.82)
262 (24.0)
247 (22.6)
246 (22.5)

226 (20.7)
236 (21.6)
244 (22.3)
386 (35.3)

131 (12.0)
204 (18.7)
250 (23.0)
507 (46.4)

31 (2.8)
115 (10.5)
211 (19.3)
735 (67.2)

Age
<65 years
>65 years
mean age (SD)
Female
Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Other
Eligibility status
Disabled
End-stage renal disease
Dual eligible
Receiving low-income cost sharing subsidy
Qualifying Chronic Conditions
Diagnosis of Hypertension
Diagnosis of Diabetes
Diagnosis of Congestive heart failure
Diagnosis of Coronary artery disease
Diagnosis of Asthma
Diagnosis of Chronic obstructive pulmonary
disease
Number of qualifying chronic conditions
<1 chronic conditions
2 chronic conditions
3 chronic conditions
4 or more chronic conditions
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Table 2-1.

Continued
Characteristics
Comorbidity
Charlson comorbidity index, mean (SD)
Mental illness*
Tobacco use disorder
Therapy complexity
No. of unique medications filled, mean
(SD)
No. of unique prescribers
No. of unique pharmacies
No. of opioids filled, mean (SD)
0 opioid filled
1 opioid filled
2-3 opioid filled
>4 opioid filled
Health services utilization
>1 physician office visits±
No. of inpatient stays, mean (SD)
No. of emergency department visits, mean
(SD)

Period 1
N (%)

Period 2
N (%)

Period 3
N (%)

Period 4
N (%)

3.2 (2.7)
389 (35.6)
106 (9.7)

4.2 (3.1)
460 (42.1)
163 (14.9)

5.2 (3.3)
533 (48.8)
266 (24.4)

6.9 (3.2)
622 (57.0)
351 (32.1)

11.9 (6.2)
4.4 (2.9)
1.8 (1.3)
2.6 (4.0)
499 (45.7)
147 (13.5)
159 (14.6)
287 (26.3)

12.3 (6.4)
4.6 (3.0)
1.8 (1.3)
2.7 (4.0)
479 (43.9)
165 (15.1)
143 (13.1)
305 (27.9)

12.5 (6.5)
4.7 (3.0)
1.9 (1.3)
2.7 (3.9)
480 (44.0)
157 (14.4)
151 (13.8)
304 (27.8)

14.9 (6.3)
5.8 (3.1)
2.1 (1.4)
3.2 (4.1)
337 (31.0)
187 (17.1)
211 (19.3)
357 (32.7)

900 (82.4)
0.8 (1.4)
0.8 (2.1)

903 (82.7)
0.8 (1.4)
0.8 (2.2)

909 (83.2)
0.7 (1.4)
0.9 (2.2)

915 (83.8)
3.1 (0.9)
1.7 (2.6)

±

Physician office visits were identified using Part B claims and were defined as “location, other than a hospital, skilled nursing facility
(SNF), military treatment facility, community health center, State or local public health clinic, or intermediate care facility (ICF),
where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory
basis.”
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of depression/anxiety.
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Table 2-2.
Medication Nonadherence to Essential Chronic Disease Medications
by Therapy Class
Therapy Class

Percent Nonadherent
(PDC<80%)

1. Diabetes medications
Period 1 (n=250)
Period 2 (n=240)
Period 3 (n=232)
Period 4 (n=194)
Overall (n=916 patient-periods)
2. Cardiovascular medications
Period 1 (n=933)
Period 2 (n=942)
Period 3 (n=932)
Period 4 (n=976)
Overall (n=3,763 patient-periods)
3. COPD/Asthma medications*
Period 1 (n=169)
Period 2 (n=166)
Period 3 (n=169)
Period 4 (n=183)
Overall (n=687 patient-periods)
Diabetes, cardiovascular, and COPD/Asthma
meds combined
Period 1 (n=961)
Period 2 (n=971)
Period 3 (n=961)
Period 4 (n=994)
Overall (n=3,892 patient-periods)

41.2%
40.8%
38.8%
40.7%
40.4%
40.2%
44.5%
41.0%
47.4%
48.2%
54.4%
53.6%
49.7%
59.6%
54.3%
43.2%
45.9%
42.6%
50.9%
45.7%

COPD: chronic obstructive pulmonary disease.
*COPD/Asthma medications included controller medications (anticholinergic inhalers,
inhaled corticosteroids alone or in combination with long-acting beta-agonists (LABA),
and other COPD/asthma medications (theophylline and leukotriene modifiers).
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Table 2-3.
Bivariate Associations with Medication Nonadherence (N=2,828
Patient-Periods)
Characteristics

Adherence
N (%)

Nonadherence
N (%)

P Value

512 (33.5)
1,018 (66.5)
932 (60.9)

640 (49.3)
658 (50.7)
780 (60.1)

<0.001
0.656

538 (35.2)
992 (64.8)

365 (28.1)
933 (71.9)

<0.001

472 (30.9)
151 (9.9)
907 (59.3)

279 (21.5)
132 (10.2)
887 (68.3)

<0.001

4.3 (3.1)
282 (18.4)
635 (41.5)

4.6 (3.2)
258 (19.9)
521 (40.1)

0.030
0.330
0.462

12.9 (5.9)

13.3 (6.3)

0.174

720 (47.1)
215 (14.1)
227 (14.8)
368 (24.1)
4.5 (2.8)
1.8 (1.1)

503 (38.8)
195 (15.0)
167 (12.9)
433 (33.4)
5.1 (3.2)
2.0 (1.4)

<0.001

1,333 (87.1)

1,070 (82.4)

0.001

Age
<65 years
>65 years
Female
Race
Non-Hispanic White/other
Non-Hispanic Black
Eligibility status
Non-dual and non-LIS
Non-dual LIS
Dual LIS
Comorbidity
Charlson comorbidity index, mean (SD)
Diagnosis of tobacco abuse disorder
Mental illness*
Therapy complexity
No. of unique medications filled, mean
(SD)
Opioid Medication Use
0 opioid medication filled
1 opioid medication filled
2-3 opioid medications filled
>4 opioids medications filled
No. of unique prescribers
No. of unique pharmacies
Health care utilization
>1 physician office visits

<0.001
<0.001

Significant at P<0.05. The bivariate tests included lagged effects of comorbidity, therapy
complexity-related, and health care utilization factors.
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
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Table 2-4.
Multivariate Association with Medication Nonadherence (N=2,828
Patient-Periods)
Characteristics
<65 years
Female
Non-Hispanic black
Non-dual Non-LICS (Ref)
Non-dual LICS
Dual LICS
Comorbidity
Charlson comorbidity index
Mental illness*
Diagnosis of tobacco abuse disorder
Medication related factors
No. of unique medications filled
Opioid Medication Use
0 opioid medication filled (Ref)
1 opioid medication filled
2-3 opioid medications filled
>4 opioid medications filled
No. of unique prescribers
No. of unique pharmacies
Health care utilization
>1 physician office visits

Nonadherence
Odds Ratio (95% CI)
2.15 (1.54-2.99)
1.01 (0.75-1.38)
1.17 (0.84-1.63)

P Value

1.10 (0.66-1.83)
1.47 (1.02-2.13)

0.708
0.039

1.02 (0.98-1.07)
0.79 (0.58-1.08)
0.82 (0.58-1.16)

0.330
0.140
0.264

0.96 (0.93-0.98)

0.006

1.30 (0.93-1.82)
1.02 (0.71-1.46)
1.94 (1.34-2.82)
1.09 (1.03-1.15)
1.02 (0.92-1.14)

0.128
0.914
<0.001
0.003
0.671

0.57 (0.40-0.81)

0.002

<0.001
0.931
0.343

Significant at P<0.05. The model included lagged effects of comorbidity, therapy
complexity-related, and health care utilization factors.
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
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compared to patients with no opioid fill (odds ratio (OR), 1.94; 95% confidence interval
(CI), 1.34-2.82; P<0.001). Compared to patients with no mental illness, those with
mental illness had lower odds of nonadherence, however this association was not
statistically significant (OR, 0.79; CI, 0.58-1.08; P=0.140). Among sociodemographic
factors, patients 22-64 years of age were more likely to be nonadherent than patients >65
years (OR: 2.15; CI: 1.54-2.99; P<0.001), and dual beneficiaries who received LICS
were more likely to be nonadherent than non-dual beneficiaries with no LICS CI, 1.022.13; P=0.039). Among therapy complexity-related factors, patients who had higher
number of unique prescribers were more likely to be nonadherent (OR, 1.09; CI, 1.031.15; P=0.003), whereas patients who filled higher number of different medications were
less likely to be nonadherent (OR, 0.96; CI, 0.93-0.98; P=0.006). Finally, we found that
patients who had >1 physician office visits in the previous period were less likely to be
nonadherent to their essential chronic medications (OR, 0.57; CI, 0.40-0.81; P=0.002).
Table 2-5 shows the multivariate associations among Medicare beneficiaries >65
years of age. Risk factors for nonadherence in this age group included >4 opioid
medications filled in the previous period and higher number of unique prescribers.
Additionally, we found that >1 physician office visits in the previous period was
protective against nonadherence. Table 2-6 shows the multivariate associations among
Medicare beneficiaries <65 years of age. Risk factors for nonadherence included >4
opioid medications filled in the previous period and dual LICS status. Higher number of
unique medications filled was found to be protective against nonadherence.
Sensitivity Analysis
Our main adherence definition—based on patients who had at least >2 fills in a
period—may underestimate nonadherence because it did not include patients who had
only one fill or did not fill their medications in subsequent periods. Using the alternative
PDC definition that assumes continuous chronic disease drug class use once begun (>2
fills for a drug class in a period), proportion of patients who were nonadherent was about
13% higher (58.4%) (Appendix A, Table A-2). The multivariate model using this
alternate PDC calculation demonstrated similar findings in terms of direction and
statistical significance to our main analysis in terms of age, dual LICS status, number of
different medications filled, unique prescribers, and physician office visits. However,
there were a few differences: comorbidity index was found to be significantly associated
with nonadherence and the association between opioid medication fill and nonadherence
was no longer statistically significant (Appendix A, Table A-3). Additionally, in the
sensitivity analysis using the alternative PDC criteria of >1 medication fill for our main
PDC definition (Appendix A, Table A-4), the study findings were similar in terms of
significance and directionality to our main multivariate analysis.
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Table 2-5.
Multivariate Association with Medication Nonadherence Among
Medicare Beneficiaries ≥65 Years of Age (N=1,676 Patient-Periods)
Characteristics
Female
Non-Hispanic black
Non-dual Non-LICS (Ref)
Non-dual LICS
Dual LICS
Comorbidity
Charlson comorbidity index
Mental illness*
Diagnosis of tobacco abuse disorder
Medication related factors
No. of unique medications filled
Opioid Medication Use
0 opioid medication filled (Ref)
1 opioid medication filled
2-3 opioid medications filled
>4 opioid medications filled
No. of unique prescribers
No. of unique pharmacies
Health care utilization
>1 physician office visits

Nonadherence
Odds Ratio (95% CI)
1.15 (0.77-1.71)
1.09 (0.71-1.68)

P Value

0.90 (0.48-1.72)
1.29 (0.84-1.97)

0.759
0.242

1.03 (0.97-1.10)
0.73 (0.48-1.11)
0.78 (0.45-1.35)

0.330
0.143
0.373

0.96 (0.91-1.02)

0.155

1.30 (0.85-2.00)
1.04 (0.66-1.63)
1.89 (1.14-3.12)
1.14 (1.04-1.24)
0.95 (0.80-1.13)

0.228
0.876
0.013
0.004
0.588

0.50 (0.31-0.80)

0.004

0.494
0.684

Significant at P<0.05. The model included lagged effects of comorbidity, therapy
complexity-related, and health care utilization factors.
*Mental illness was defined as ≥1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
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Table 2-6.
Multivariate Association with Medication Nonadherence Among
Medicare Beneficiaries <65 Years of Age (N=1,152 Patient-Periods)
Characteristics
Female
Non-Hispanic black
Non-dual Non-LICS (Ref)
Non-dual LICS
Dual LICS
Comorbidity
Charlson comorbidity index
Mental illness*
Diagnosis of tobacco abuse disorder
Medication related factors
No. of unique medications filled
Opioid Medication Use
0 opioid medication filled (Ref)
1 opioid medication filled
2-3 opioid medications filled
>4 opioid medications filled
No. of unique prescribers
No. of unique pharmacies
Health care utilization
>1 physician office visits

Nonadherence
Odds Ratio (95% CI)
0.90 (0.57-1.43)
1.34 (0.78-2.30)

P Value

0.99 (0.80-4.92)
2.58 (1.18-5.61)

0.139
0.017

0.71 (0.41-1.23)
0.86 (0.54-1.36)
0.83 (0.54-1.28)

0.221
0.522
0.397

0.95 (0.90-0.99)

0.035

1.16 (0.68-1.96)
0.85 (0.49-1.47)
1.83 (1.08-3.11)
1.03 (0.96-1.10)
1.09 (0.95-1.26)

0.583
0.570
0.025
0.370
0.205

0.71 (0.41-1.23)

0.221

0.648
0.296

Significant at P<0.05. The model included lagged effects of comorbidity, therapy
complexity-related, and health care utilization factors.
*Mental illness was defined as ≥1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
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DISCUSSION
This study is the first to focus specifically on the prevalence and factors
associated with medication nonadherence in super-utilizers with chronic conditions. We
found high rates of medication nonadherence among super-utilizers with chronic
conditions. Specifically, we found that the overall nonadherence rate for essential chronic
disease medications ranged from 45.7% to 58.4%, with the highest rate for
COPD/Asthma medications (54.3% to 64.4%). The high rates of nonadherence found in
this study are similar to those previously found in patients using diabetes, cardiovascular,
and COPD/asthma medications.3,15,81-83 However, this study extends these findings to
super-utilizing Medicare population and provides important information to the superutilizer literature. We not only found high rates of nonadherence among super-utilizers
but also saw an increase in the nonadherence rates in the final 6-month period when
patients had more frequent hospitalizations and ED visits. The study findings suggest that
medication nonadherence is a significant problem among super-utilizers with chronic
conditions, and greater efforts may be needed to address this issue.
Our study shows that most super-utilizers have high rates of mental illness and
opioid use. During the final 6-month evaluation period, 57% were diagnosed with
depression or anxiety or had filled antidepressants or anxiolytics, and 69% had filled
opioid medications. A substantial amount of opioid utilization is likely driven by the high
prevalence of chronic pain in the SafeMed population as documented in a previous
study.57 To our knowledge this is the first study to document the association between
opioid medication fill and medication nonadherence among super-utilizers and provides
evidence of high opioids use as a risk factor for medication nonadherence. These findings
highlight the barrier to achieving optimal adherence in super-utilizers due to high opioid
use and the need for effective strategies to address medication nonadherence among
opioid-consuming super-utilizers. Our results for depression/anxiety were not consistent
with the previous studies which found these conditions to be associated with
nonadherence.24,84-87 We did not find any significant association of anxiety/depression or
filling anxiolytic/antidepressants with nonadherence to essential chronic medications in
the main analysis.
This study provides insight into the characteristics of super-utilizers who are at
higher risk of medication nonadherence. In this study, non-elderly Medicare beneficiaries
represented 43% of the study population, approximately 92% of whom received LICS,
and 80% were both dual-eligible and LICS recipients. Unlike other studies based on
Medicare data that have shown better or similar medication adherence for duals and those
receiving LICS compared to non-dual non-LICS beneficiaries,88,89 we found lower
adherence for duals receiving LICS. This is probably because our study population,
unlike those of previous studies, had high representation of younger dual eligible
beneficiaries, who had on average higher comorbidity index values and opioid
medication use than patients >65 years of age. Moreover, previous studies conducted on
different populations have shown that young age is associated with lower medication
adherence.1,3 Our study findings show that medication cost subsidies are not enough to
achieve optimal adherence in these high-risk patients, especially for non-elderly
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Medicare beneficiaries. The highly statistically significant and large effect size of the
association between age and medication nonadherence demonstrates the need for better
targeting of the non-elderly Medicare group with medication management interventions.
Our sub-group analysis shows that the factors associated with nonadherence vary across
age groups. Examining associations separately in the two age groups may help
researchers to better target these high utilizing patient populations with medication
management interventions.
The study found that higher physician office visits were associated with
significant higher medication adherence, consistent with the findings of other studies.3,5
The statistically strong association between physician office visits and lower
nonadherence suggests the importance of making routine visits to providers who can play
a significant role in helping patients to adhere to their essential chronic medications. This
finding may also be an indicator for more health consious patients who are more likely to
visit their providers.
Of note, increased number of different medications filled was associated with
lower odds of nonadherence. Other studies evaluating this relationship have reported
mixed results. For instance, Bailey and colleagues found that among Tennessee’s
Medicaid patients with hypertension, the number of hypertensive drug classes filled was
associated with lower odds of nonadherence.3 Similarly, Choudhry and colleagues found
that in patients who were prescribed a cardiovascular medication, those with a large
number of concurrent medications were more likely to be adherent.73 However, Chapman
and colleagues found that patients consuming a higher number of other medications had
lower adherence to lipid lowering and antihypertensive medications.90 Filling a higher
number of concurrent medications may represent behavioral characteristics of patients
who are more likely to use a higher number of medications and also adhere to their
therapy. When examining other therapy complexity-related factors, we found that a
higher number of unique prescribers was associated with higher odds of nonadherence.
This finding was consistent with the finding of Choudhry and colleagues who also found
higher number of prescribers being associated with poor adherence.73
This study has important implications. The literature on super-utilizers is sparse
and mainly focuses on describing the population and their hospitalization patterns.56,57 To
our knowledge, this study is the first to focus on the issue of medication nonadherence in
super-utilizers with chronic conditions. The risk factors identified in this study may
enable accountable care organizations and managed care organizations identify superutilizing populations in need of medication management interventions. Managing
medication-related adverse events and improving medication adherence among
vulnerable super-utilizers is critical for hospitals and payers, since 75% of the hospital
readmissions among Medicare population are considered potentially preventable,
resulting in $12 billion in unnecessary Medicare spending each year and subjecting
hospitals to readmission penalties.46 Our findings suggest that super-utilizers using >4
opioid medications are at particular risk for nonadherence and may merit targeted
medication management interventions to support essential chronic disease medication
adherence. Given the magnitude and clinical importance of medication nonadherence in
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this population, a more collaborative and holistic approach may be needed to improve
adherence in this high-risk population, who experience frequent care transitions exposing
them to higher drug therapy problems and medication discrepancies. Medication
management interventions conducted on other populations have demonstrated mixed
results,17,19,44,45 and care transitions programs targeting super-utilizers have not primarily
focused on medication management.65,91 For instance, Pringle and colleagues evaluated
the impact of a large-scale, pharmacy-based intervention on five chronic medication
classes among Medicare, Medicaid, or commercial patients and found that, compared to
the control group, the intervention group had improved adherence for all medication
classes.43 However, Kripalani and colleagues, who examined the effect of pharmacist
interventions on clinically important medical errors after hospital discharge among
Medicare, Medicaid, or private pay patients, did not find any positive effect of these
interventions on medication errors.19 Our results suggest the potential for novel care
transitions programs aimed at improving medication adherence.
Our study is also subject to several limitations. First, the study used administrative
data and had to rely on the variables that were available in the database. Medicare claims
data does not capture some of the important variables such as health literacy, social
support, satisfaction with health care, and other healthcare system factors that may impact
medication adherence in vulnerable super-utilizers. Second, although pharmacy fill data
is widely used to assess medication adherence, we cannot be certain that patients who fill
medications are also using them appropriately. To address limitations of using claims
based PDC, we calculated PDC using two different definitions, which allowed for
checking the reliability of our main findings. Using these approaches, the overall
nonadherence rate ranged from 45.7% to 58.4% and most of the findings of multivariate
models remained similar. Given that the main approach could overestimate adherence
and the alternative methods could underestimate adherence, we suspect that the
population estimates for nonadherence of these super-utilizers could lie somewhere
between the nonadherence ranges reported in this study. Third, the PDC measure for
calculating adherence is an indirect method and may not accurately capture medication
use and is likely to be biased for inhalation products that are prescribed for Asthma and
COPD. Finally, since this study is based on super-utilizers living in Memphis, TN, the
study findings may only be generalizable to similar populations and similar settings
across the country.
CONCLUSION
In summary, the overall medication nonadherence rate for essential chronic
disease medications was high among super-utilizers, especially in patients using
COPD/Asthma medications. Previously identified factors—including physician office
visits, a higher number of medications—were found to protect against nonadherence,
while young age, dual LICS status, and higher number of unique prescribers predicted
nonadherence. Of note, opioid medication use was identified as a novel and significant
risk factor for essential medication nonadherence in super-utilizers with chronic
conditions.
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CHAPTER 3. ASSOCIATION BETWEEN MEDICATION NONADHERENCE
AND INPATIENT AND EMERGENCY DEPARTMENT USE IN SUPERUTILIZERS WITH CHRONIC CONDITIONS
BACKGROUND
Consistent and long-term use of prescription medications is critical for the
treatment of chronic conditions, such as heart disease, diabetes, hypertension, and chronic
lung disease. Nonadherence to needed drugs could be a major barrier to achieving
optimal treatment goals, especially among high-risk patient populations. Super-utilizers
represent one such vulnerable patient population — patients with disproportionately high
inpatient and emergency department (ED) use, who have multiple chronic conditions
(MCC) and use multiple concurrent medications to treat these conditions.13,55,56 The cost
of caring for super-utilizers is high, with estimates showing that they represent only 3 to
5% of the U.S. population, but account for 30 to 50% or more of total spending.56,70
Additionally, these super-utilizing patients experience frequent transitions of care and are
particularly vulnerable to experiencing drug therapy problems, medication discrepancies,
and medication nonadherence at each care transition.13,19
Previous studies using longitudinal data have shown improved medication
adherence to be associated with lower inpatient and ED use. Roebuck and colleagues
found that improved medication adherence was associated with lower hospitalization and
ED use in patients with congestive heart failure, hypertension, diabetes, or dyslipidemia.5
Another study by Jha and colleagues also found lower hospitalization or ED rates
associated with improved adherence to diabetes medications.4 Despite widespread
recognition that medication nonadherence plays a significant role in hospitalizations,
such associations have not been established for super-utilizers with chronic conditions.
Given the increased focus on reducing the disproportionate health care utilization and
costs in this patient population, it is important to understand whether nonadherence to
essential chronic medications contributes to their high inpatient and ED use.
High rates of mental illness and chronic pain have been reported among superutilizing patient populations.56-58 Additionally, evidence from our previous study on
Medicare super-utilizers demonstrates that along with the high prevalence of medication
nonadherence and mental illness, these patients have higher rates of opioid medication
use (Chapter 2). However, little is known whether these factors are associated with high
inpatient and ED use. A recent study found that opioid use is common after
hospitalization among Medicare beneficiaries.92 However, it is not clear whether recent
opioid use has any association with high health care utilization. Using longitudinal
Medicare administrative data, we examined the association between medication
nonadherence and inpatients and ED use in a cohort of Medicare super-utilizers with
chronic conditions. Additionally, we also evaluated if other risk factors, including mental
illness and opioid medication use, are associated with inpatient and ED utilization in this
vulnerable high-risk population.
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METHODS
Design and Setting
SafeMed Program is a Centers for Medicare and Medicaid Services (CMS) Health
Care Innovations Award funded care transitions program with a focus on medication
management.60 The program targeted super-utilizers from medically underserved areas
admitted to a non-profit hospital system in Memphis, TN from February 2013 to May
2015. Using Medicare administrative data, we conducted a retrospective panel data
analysis of the 2-year baseline data for Medicare Part D beneficiaries meeting the
SafeMed Program eligibility criteria during the enrollment period from February 1, 2013
to December 31, 2014. The study included SafeMed eligible patients because they were
diagnosed with chronic conditions (hypertension, diabetes mellitus, congestive heart
failure (CHF), coronary artery disease (CAD), diabetes mellitus, asthma, or chronic
obstructive pulmonary disease (COPD)) that have been identified as ambulatory caresensitive conditions for which outpatient care improvements can reduce inpatient
utilization.57 The two-year baseline data for each patient was divided into four 6-month
patient-periods, the last 6-month period being the qualifying period for the SafeMed
Program. Previous studies on super-utilizers have shown that super-utilizer status is not
consistent, and it changes over time.56,57 The panel design enabled us to examine the
changes in medication adherence and health care utilization over the 2-year period prior
to the intervention and to understand whether the time-varying factor, medication
nonadherence, was associated with inpatient and ED utilization.
Study Population
This study included Medicare beneficiaries who were eligible for the SafeMed
Program during a portion of the enrollment period between February 2013 and December
2014. Patients were enrolled in the SafeMed Program during an inpatient admission or an
observation stay (index hospitalization). SafeMed Program eligibility was based on the
following inclusion criteria: 1) adults aged 18 years or older with continuous Medicare
enrollment, 2) >2 hospital admissions in the past six months OR 1 inpatient admission
and >2 ED visits in the past six months prior to the index admission, and 3) diagnosis of
>1 of the following chronic conditions: hypertension, CHF, CAD, diabetes mellitus,
asthma, or COPD.
Additionally, patients were excluded from the SafeMed Program if the primary
reason for index admission was related to cancer, pregnancy, or a surgical procedure for
an acute problem following the approach of Jencks and colleagues recognizing that
utilization for these conditions is less likely to be affected by outpatient chronic disease
care or medication management.77 Patients were also excluded if they had diagnoses of
active psychosis, drug abuse, substance abuse or suicidal ideation during the index
admission, or if they were discharged to a skilled nursing facility or hospice care because
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of evidence suggesting that high utilization in these patient populations may be less
amenable to outpatient intervention.57
Of the 1,714 Medicare patients meeting SafeMed inclusion and exclusion criteria
above, the final sample included the 1,092 (63.7%) who were continuously eligible for
Medicare Part D during the 2-year evaluation period and who had filled at least one of the
seventeen drug classes during the 2-year baseline evaluation period: These drug classes
included angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor
blockers (ARB), statins, antiplatelet agents, beta-blockers, calcium channel blockers,
diuretics, alpha-1 blockers, central alpha-2 agonists, direct vasodilators, sulfonylureas,
biguanides, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors,
anticholinergic inhalers, inhaled corticosteroids alone or in combination with long-acting
beta-agonists (LABA), and other COPD/asthma medications (theophylline and
leukotriene modifiers).
Outcome Variables
This study included two outcomes: 1) total number of inpatient and observation
stays and 2) total number of ED visits, measured for each 6-month period. Data on
inpatient stays was obtained using MEDPAR (Medical Provider Analysis and Review)
data files. Additionally, data on observation stays and ED visits were obtained using
Medicare outpatient revenue center data files (revenue center codes for ED visits: 04500459, 0981; revenue center codes for observation stays: 0762). We excluded observation
stays and ED visits that resulted in an inpatient admission.
Independent Variables
Medication nonadherence
The Medicare Part D drug event data was used to assess medication
nonadherence. Medication nonadherence was measured as interval-based proportion of
days covered (PDC).21 PDC was measured based on total number of days’ supply for
each drug class divided by the observation time interval for each 6-month period. We
measured PDC for the drug classes mentioned above. Drugs that belonged to the same
therapeutic class (example, amlodipine, and nifedipine in the calcium channel blockers)
were considered interchangeable. Based on the evidence-based guideline, ACE inhibitors
and ARB were considered a single class for this study.78 Antiplatelet agents did not
include aspirin because aspirin is usually purchased without a prescription (over-thecounter) and is not included in Part D claims data. Moreover, we did not include insulin
since the days’ supply information on this drug class is not accurate.79
Using interval-based PDC approach, patients were followed continuously from
the time they had >2 fills during a 6-month period for a drug class, to the last 6-month
period. The numerator was defined as the number of days of medication supply between
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the first and last prescription in a period, and the denominator was defined as the number
of days during the interval from the index date to the last day of that period. For the
numerator, if the days’ supply extended into the next period, it contributed to both
periods. For the denominator, we used the first day of medication fill as index date only if
patients had >2 fill for a drug class for the first time in a period. If patients filled >2
medications for a drug class in any of the previous periods, we considered denominator
as 180 days. Additionally, we subtracted the inpatient days from the denominator. The
average PDC measure was calculated at the patient-level by adding the PDC for each
drug class and then dividing by the number of drug class used by the patient. Patients
were then classified as nonadherent if they had PDC<80% over the 6-month period.
Adherence was also measured based on therapy-specific medication adherence
classifications, which included diabetes, cardiovascular, and COPD/asthma medications.
Additionally, as a sensitivity analysis, we measured adherence by changing the fill
criteria of >2 medication fills for a drug class to >1 medication fill.
Other covariates
In addition to the primary adherence variable, we assessed mental illness,
substance use disorder, and opioid medication use for each 6-month period. We identified
patients with mental illness if they had a diagnosis of depression or anxiety (at least 1
diagnosis claim present in Medicare inpatient, outpatient, or Part B claims) or >1
anxiolytic or antidepressant fill. Opioid medication use was based on number of opioid
medication fill (0 fill, 1 fill, 2-3 fills, >3 fills). Additionally, we identified patients with
substance use disorder if they had a diagnosis of tobacco use disorder.
Sociodemographic variables were assessed using Medicare beneficiary summary
files. Factors assessed at baseline included age, gender, race/ethnicity, disability status,
and end-stage renal disease (ESRD) status. Disability was not included in the multivariate
models since everyone <65 years of age was also disabled. Additionally, ESRD was not
included in the models since Charlson comorbidity index includes ESRD. Other
sociodemographic factors measured for each 6-month period included whether patients
were fully or partially eligible as dual beneficiaries in >1 month and whether patients
received low-income cost sharing subsidy (LICS) for the index drug classes. Since the
income threshold for receiving LICS is higher than to be eligible for Tennessee Medicaid,
we combined them to create a variable with 3 mutually exclusive groups (non-dual nonLICS, non-dual LICS, and dual LICS).
To control for the presence of other diseases, we used the ICD-9 diagnosis codes
present on at least 1 Medicare inpatient, outpatient, or Part B claim, to identify patients in
each 6-month period having comorbidities. Overall comorbidity was measured using the
University of Manitoba SAS Macro for Charlson comorbidity index.80 Other control
variables assessed for each 6-month period included >1 physician office visits, number of
unique medications filled, and number of unique prescribers.
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Statistical Analysis
For multivariate analyses, we pooled observations from the four 6-month periods.
The unit of analysis was patient-period. The viability of using a random effects model or
a fixed effects model was tested using the Hausman specification test.93 For both
outcomes, the null hypothesis was rejected (P<0.01) indicating that a fixed effects model
would be superior to account for potential endogeneity that arises if an unobserved
characteristic is related to both the independent variables and the outcome. One such bias
is known as ‘healthy user effect’—people who are adherent to their medications also
engage in health-enhancing behavior and are different from nonadherent individuals.94
Thus, we used fixed effects negative binomial model at the patient level to control for this
potential problem. We estimated separate models for each age group (i.e., <65 and >65
years) to understand associations specific to these Medicare age groups. We included
lagged effects of all independent factors in the models.
In addition to the main models, we also conducted multivariate fixed effects
analyses to examine the association between medication nonadherence and inpatient and
ED utilization across different therapy classes—diabetes, cardiovascular, and
COPD/asthma medication class. Additionally, to investigate the association between
time-invariant factors including race, dual LICS status and inpatient and ED utilization,
we conducted a random effects model. As sensitivity analyses, we ran models by
changing the adherence measure criteria of >2 medication fills to >1 fill. All data
analyses were conducted using SAS 9.4 and STATA 13. Variables in the multivariate
models with P<0.05 were considered significant.
RESULTS
Characteristics of the study subjects (N=1,092) in each 6-month evaluation period
are shown in Table 3-1. The mean age for the study population was 65.1, and 43.0%
were <65 years of age. The study subjects were predominantly female (58.8%), nonHispanic black (68.6), dual eligible (63.7%), and received LICS (68.7%). In the fourth
period, which was the qualifying period for the SafeMed Program, patients had a mean of
3.1 (0.9) inpatient stays and 1.7 (2.6) ED visits, which was higher than previous periods.
Additionally, in the same period, 97.2% of patients had >2 chronic conditions, 57.0% had
mental illness, and 69.0% filled >1 opioid medications. The patterns of medication
adherence among the study subjects during each 6-month evaluation period is shown in
Figure 3-1. The mean PDC for patients decreased progressively from period 1 to period
4; mean PDC was 80.3% in period 1 and declined to 63.0% in period 4. Using the 80%
PDC cutoff, we found overall nonadherence rates for all essential drug classes in the four
periods to be 43.2%, 56.1%, 65.5%, and 72 8%, respectively (data not shown).
Table 3-2 displays results for the multivariate associations between medication
nonadherence and inpatient stays and ED visits by therapy class, using fixed effects
negative binomial models. For the three therapy classes displayed — diabetes,
cardiovascular, and COPD/asthma — the adjusted models indicated that the incidence of
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Table 3-1.

Characteristics of SafeMed Eligible Patients in Each 6-Month Patient-Period (N=1,092)

Characteristics

Period 1
N (%)

Period 2
N (%)

Period 3
N (%)

Period 4
N (%)

468 (42.9)
624 (57.1)
65.1 (14.5)
642 (58.8)

-

-

-

-

-

-

326 (29.9)
749 (68.6)
17 (1.6)

-

-

-

407 (37.3)
324 (29.7)
696 (63.7)
750 (68.7)

694 (63.6)
790 (72.3)

697 (63.8)
791 (72.4)

692 (63.4)
803 (73.5)

852 (78.0)
571 (52.3)
338 (31.0)
368 (33.7)
134 (12.3)
246 (22.7)

950 (87.0)
638 (58.4)
467 (42.8)
481 (44.1)
199 (18.2)
343 (31.4)

1,028 (94.1)
696 (63.7)
603 (55.2)
590 (54.0)
262 (24.0)
448 (41.0)

1,086 (99.5)
784 (71.8)
799 (73.2)
785 (71.9)
377 (34.5)
583 (53.4)

335 (30.82)
262 (24.0)
247 (22.6)
246 (22.5)

226 (20.7)
236 (21.6)
244 (22.3)
386 (35.3)

131 (12.0)
204 (18.7)
250 (23.0)
507 (46.4)

31 (2.8)
115 (10.5)
211 (19.3)
735 (67.2)

Age
<65 years
>65 years
mean age (SD)
Female
Race/Ethnicity
Non-Hispanic white
Non-Hispanic black
Other
Eligibility status
Disabled
End-stage renal disease
Dual eligible
Receiving low-income cost sharing subsidy
Qualifying Chronic Conditions
Diagnosis of Hypertension
Diagnosis of Diabetes
Diagnosis of Congestive heart failure
Diagnosis of Coronary artery disease
Diagnosis of Asthma
Diagnosis of Chronic obstructive pulmonary disease
Number of qualifying chronic conditions
<1 chronic conditions
2 chronic conditions
3 chronic conditions
4 or more chronic conditions
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Table 3-1.

Continued

Characteristics
Comorbidity
Charlson comorbidity index, mean (SD)
Mental illness*
Tobacco use disorder
Therapy complexity
No. of unique index drug classes filled, mean (SD)
No. of opioids filled, mean (SD)
0 opioid filled
1 opioid filled
2-3 opioid filled
>4 opioid filled
Health services utilization
≥1 physician office visits
No. of inpatient stays, mean (SD)
No. of emergency department visits, mean (SD)
Super-utilizers

Period 1
N (%)

Period 2
N (%)

Period 3
N (%)

Period 4
N (%)

3.2 (2.7)
389 (35.6)
106 (9.7)

4.2 (3.1)
460 (42.1)
163 (14.9)

5.2 (3.3)
533 (48.8)
266 (24.4)

6.9 (3.2)
622 (57.0)
351 (32.1)

3.9 (2.1)
2.6 (4.0)
499 (45.7)
147 (13.5)
159 (14.6)
287 (26.3)

4.0 (2.1)
2.7 (4.0)
479 (43.9)
165 (15.1)
143 (13.1)
305 (27.9)

3.9 (2.1)
2.7 (3.9)
480 (44.0)
157 (14.4)
151 (13.8)
304 (27.8)

4.3 (2.0)
3.2 (4.1)
337 (31.0)
187 (17.1)
211 (19.3)
357 (32.7)

900 (82.4)
0.8 (1.4)
0.8 (2.1)
168 (15.4)

903 (82.7)
0.8 (1.4)
0.8 (2.2)
187 (17.1)

909 (83.2)
0.7 (1.4)
0.9 (2.2)
155 (14.2)

915 (83.8)
3.1 (0.9)
1.7 (2.6)
1,192 (100.0)

Physician office visits were identified using Part B claims and were defined as “location, other than a hospital, skilled nursing facility
(SNF), military treatment facility, community health center, State or local public health clinic, or intermediate care facility (ICF),
where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory
basis.” *Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of depression/anxiety. Super-utilizers defined
as >3 inpatient admissions OR >2 inpatient admissions and >2 emergency department visits in 6 months.
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Figure 3-1.

Proportion of Days Covered (PDC) During Each 6-Month Period
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Table 3-2.
Multivariable Results for Inpatient Stays and Emergency Department
Visits by Therapy Class Using Fixed Effects Model
Therapy Class
Diabetes Medications
Nonadherence (overall sample)
Nonadherence (<65 years)
Nonadherence (>65 years)
Cardiovascular Disease Medications
Nonadherence (overall sample)
Nonadherence (<65 years)
Nonadherence (>65 years)
COPD or Asthma Medications
Nonadherence (overall sample)
Nonadherence (<65 years)
Nonadherence (>65 years)

Inpatient Stays
IRR (95% CI) P Value

ED Visits
IRR (95% CI) P Value

1.22 (1.02-1.45)
0.97 (0.72-1.30)
1.38 (1.11-1.72)

0.026
0.823
0.004

1.17 (0.95-1.45)
1.23 (0.86-1.75)
1.16 (0.89-1.52)

0.132
0.256
0.266

1.42 (1.25-1.61)
1.35 (1.13-1.62)
1.42 (1.19-1.69)

<0.001
0.001
<0.001

1.14 (0.99-1.31)
1.23 (1.02-1.49)
1.05 (0.86-1.29)

0.070
0.033
0.622

1.35 (1.00-1.82)
1.07 (0.66-1.73)
1.48 (1.01-2.18)

0.048
0.781
0.047

1.24 (0.87-1.75)
1.21 (0.77-1.91)
1.11 (0.65-1.89)

0.237
0.403
0.712

Significant at P<0.05. IRR: Incidence Rate Ratio. ED Visits: Emergency department
visits. COPD: Chronic Obstructive Pulmonary Disease.
We used fixed effects negative binomial models at patient level. The adjusted models
included lagged effects of medication nonadherence, Charlson comorbidity index, mental
illness, opioid medication filled, number of medications filled, number of different
prescribers, and >1 physician office visits.
Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
Diabetes Medications: Sample for inpatient stays - nonadherence (overall): 855 patientperiods, nonadherence (<65 years): 312 patient-periods, nonadherence (>65 years): 543
patient-periods.
Sample for ED visits – nonadherence (overall): 624 patient-periods, nonadherence (<65
years): 251 patient-periods, nonadherence (>65 years): 373 patient-periods.
Cardiovascular Disease Medications: Sample for inpatient stays – nonadherence
(overall): 2,893 patient-periods, nonadherence (<65 years): 1,177 patient-periods,
nonadherence (>65 years): 1,716 patient-periods.
Sample for ED visits – nonadherence (overall): 2,133 patient-periods, nonadherence (<65
years): 945 patient-periods, nonadherence (>65 years): 1,188 patient-periods.
COPD or Asthma Medications: Sample for inpatient stays – nonadherence (overall): 513
patient-periods, nonadherence (<65 years): 209 patient-periods, nonadherence (>65
years): 304 patient-periods.
Sample for ED visits – nonadherence (overall): 359 patient-periods, nonadherence (<65
years): 158 patient-periods, nonadherence (>65 years): 201 patient-periods.
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inpatient stays was higher for nonadherent patients (P<0.05) compared with adherent
patients. In the overall sample, the number of inpatient stays were 22% higher in patients
not adherent to their diabetes medications (Incidence Rate Ratio (IRR), 1.22; Confidence
Interval (CI), 1.02-1.45; P=0.026), 42% higher in patients who were nonadherent to their
cardiovascular disease medications (IRR, 1.42; CI, 1.25-1.61; P<0.001), and 35% higher
in patients not adherent to their COPD/asthma medications (IRR, 1.35; CI, 1.00-1.82;
P=0.048). Additionally, the adjusted analyses for ED visits showed that in the overall
sample, nonadherence to essential chronic medications was not significantly associated
with ED visits (P<0.05). When examining the results stratified by age, we found that the
association between nonadherence to CVD medications and inpatient admissions was
significant for both age groups. Whereas for diabetes and COPD/asthma therapy classes,
the association with inpatient admissions was significant only among elderly Medicare
beneficiaries. Additionally, the association between nonadherence to CVD medications
and ED visits was significant for non-elderly Medicare patients.
Table 3-3 shows the multivariate associations among Medicare beneficiaries >65
years of age. Patients who were nonadherent to their essential chronic medications had
57% higher inpatient stays (IRR, 1.57; CI, 1.33-1.87; P<0.001) compared with adherent
patients. The association between medication nonadherence and ED visits was not
statistically significant. Among other factors, mental illness was associated with 54%
higher inpatient stays (IRR, 1.54; CI, 1.20-1.98; P=0.001) and 46% higher ED visits
(IRR, 1.46; CI, 1.11-1.93; P=0.007). Opioid medication fills in the previous period were
protective against inpatient and ED utilization among elderly Medicare beneficiaries,
however, these associations were not statistically significant.
Table 3-4 displays the same results among Medicare beneficiaries <65 years of
age. Patients who were nonadherent to their essential chronic medications had 41%
higher inpatient stays (IRR, 1.41; CI, 1.17-1.69; P<0.001) and 25% higher ED visits
(IRR, 1.25; CI, 1.04-1.51; P=0.020) compared with adherent patients. Mental illness was
not significantly associated inpatient and ED use, while tobacco use disorder was
significantly associated with higher inpatient utilization (IRR, 1.61; CI, 1.17-2.22;
P=0.003). Additionally, among non-elderly Medicare beneficiaries, opioid medication
use in the previous period was not significantly associated with inpatient and ED use.
When examining the association between race and dual-LICS status with inpatient
and ED visits (Appendix B, Tables B-1 and B-2), random effects models showed that
among elderly Medicare beneficiaries, non-Hispanic blacks had significantly higher ED
use, and dual eligible beneficiaries with LICS had significantly higher inpatient and ED
utilization. Similarly, among non-elderly Medicare beneficiaries, dual beneficiaries with
LICS had significantly higher ED utilization. In sensitivity analyses using the alternative
PDC criteria of >1 medication fill, our results were similar in terms of significance and
directionality to our main analyses (Appendix B, Tables B-3 and B-4).

39

Table 3-3.
Multivariable Results for Inpatient Stays and Emergency Department
Visits Among Medicare Beneficiaries ≥65 years
Characteristics
Overall medication nonadherence
Comorbidity
Charlson comorbidity index
Mental illness
Tobacco use disorder
Opioid medication filled
0 opioid fill (ref)
1 opioid fill
2-3 opioid fill
>3 opioid fill
Number of unique medications
filled
Number of unique prescribers
>1 physician office visit

Inpatient Stays
IRR (95% CI)
P Value
1.57 (1.33-1.87)
<0.001

ED Visits
IRR (95% CI) P Value
1.11 (0.91-1.34)
0.308

1.23 (1.17-1.28)
1.54 (1.20-1.98)
1.29 (0.90-1.84)

<0.001
0.001
0.166

1.16 (1.09-1.23)
1.46 (1.11-1.93)
0.79 (0.50-1.25)

<0.001
0.007
0.309

-0.96 (0.77-1.20)
0.86 (0.66-1.11)
0.87 (0.64-1.18)
1.02 (0.99-1.05)

-0.726
0.248
0.380
0.136

-0.92 (0.72-1.17)
0.90 (0.68-1.18)
0.77 (0.54-1.11)
0.97 (0.94-1.07)

-0.487
0.448
0.161
0.106

0.97 (0.92-1.02)
0.91 (0.67-1.23)

0.176
0.532

0.98 (0.93-1.04)
1.64 (1.00-2.69)

0.512
0.051

Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department
visits.
We used fixed effects negative binomial models at patient level. The models included
lagged effects of all the above factors.
Overall medication nonadherence measured at patient-level was based on eighteen index
drug classes.
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
The multivariable model with inpatient stays as outcome included 1,742 patient-periods.
The multivariable model with ED visits as outcome included 1,203 patient-periods.
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Table 3-4.
Multivariable Results for Inpatient Stays and Emergency Department
Visits Among Medicare Beneficiaries <65 years
Characteristics
Overall medication nonadherence
Comorbidity
Charlson comorbidity index
Mental illness
Tobacco use disorder
Opioid medication filled
0 opioid fill (ref)
1 opioid fill
2-3 opioid fill
>3 opioid fill
Number of unique medications
filled
Number of unique prescribers
>1 physician office visit

Inpatient Stays
IRR (95% CI) P Value
1.41 (1.17-1.69)
<0.001

ED Visits
IRR (95% CI) P Value
1.25 (1.04-1.51)
0.020

1.18 (1.13-1.23)
1.14 (0.86-1.50)
1.61 (1.17-2.22)

<0.001
0.358
0.003

1.11 (1.05-1.16)
1.18 (0.88-1.58)
1.30 (0.92-1.82)

<0.001
0.277
0.135

-0.81 (0.63-1.06)
0.83 (0.63-1.09)
0.96 (0.69-1.33)
1.01 (0.98-1.04)

-0.124
0.182
0.801
0.518

-0.93 (0.70-1.24)
0.98 (0.72-1.31)
1.25 (0.87-1.79)
1.02 (0.99-1.04)

-0.614
0.873
0.230
0.263

0.98 (0.95-1.02)
0.90 (0.67-1.20)

0.365
0.454

0.98 (0.95-1.02)
0.97 (0.67-1.40)

0.315
0.857

Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department
visits
We used fixed effects negative binomial models at patient level. The models included
lagged effects of all the above factors.
Overall medication nonadherence measured at patient-level was based on eighteen index
drug classes.
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
The multivariable model with inpatient stays as outcome included 1,227 patient-periods.
The multivariable model with emergency department visits as outcome included 986
patient-periods.
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DISCUSSION
This study is the first, to our knowledge, to examine the relationship between
nonadherence, and other important factors with health care utilization in super-utilizers
with chronic conditions. In our sample of super-utilizing Medicare population with
chronic conditions, we found higher incidences of inpatient hospitalizations and ED visits
among beneficiaries who were not adherent to their essential chronic medications.
Specifically, we found that among elderly Medicare beneficiaries, nonadherence was
significantly associated with a 57% increase in inpatient hospitalizations, and among
younger beneficiaries, nonadherence was associated with 41% increase in inpatient stays
and 25% increase in ED visits. Similar associations were found across all therapy classes
examined (diabetes, cardiovascular, and COPD/asthma) in both age groups. However,
nonadherence to diabetes and COPD/asthma drugs was not significantly associated with
ED visits. Furthermore, we found that while the effects of nonadherence on inpatient
stays were seen in both age groups, the effects of nonadherence on ED visits were more
pronounced for younger Medicare patients. These findings suggest that nonelderly
Medicare beneficiaries may be at increased risk for nonadherence which may further be
associated with higher ED use. Targeted medication management interventions for
younger Medicare beneficiaries may potentially help in lowering their ED visits.
Our results provide important insights into associations between medication
nonadherence and hospitalizations and are consistent with prior research on Medicare
population which showed nonadherence to be associated with higher incidence of
hospitalizations. Simoni-Wastila and colleagues found that Medicare patients with COPD
who were adherent to their chronic medications experienced fewer hospitalizations.6 And
in a sample of Medicare patients with myocardial infarction, Zhang and colleagues found
that higher adherence with β-blockers, statins, and ACEIs/ARBs medications was
associated with lower readmission rates.39 However, unlike previous studies based on
Medicare population, this study focused specifically on super-utilizing Medicare patients
with chronic conditions. Moreover, our study population was disproportionately
represented by dual beneficiaries <65 years of age, who had on average higher
comorbidities and were more likely to be nonadherent to their essential chronic
medications than elderly patients. Given these differences, examining associations
separately in the two age groups may help researchers to better target these high utilizing
patient populations with medication management interventions. Our work extends these
findings to these vulnerable patients and suggests that improving medication adherence—
a patient behavioral factor very amenable to change—may be critical in reducing
inpatient and ED utilization among Medicare super-utilizers with chronic conditions and
complex pharmacotherapy regimens.
This analysis reinforced our previous findings that the super-utilizer status is
dynamic and changes with time.56,57 We found that of 1,092 patients who met the superutilizers criteria in the fourth period (qualifying period for the SafeMed Program), only
about 14% of them were super-utilizers in all previous periods (Table 3-1). The higher
rates of inpatient and ED utilization and lower rates of medication adherence in the last 6month period compared to the first three periods, indicate a sudden change in adherence
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and utilization in the final period. Providing early medication management interventions
to potential high-risk super-utilizers may improve adherence thereby lowering their
inpatient and ED utilization.
Similar to previous findings in super-utilizing population, we found high rates of
mental illness and substance use disorder in super-utilizers56,58 — about 57% were
diagnosed with depression or anxiety or had filled antidepressants or anxiolytics and 32%
were diagnosed with substance use disorder, in the fourth period. In our adjusted models,
we found mental illness as a risk factor for higher utilization among elderly, and
substance use disorder as a risk factor for higher inpatient utilization among younger
patients. These findings may help to identify and classify high-risk super-utilizers who
need targeted medication management interventions along with mental health and social
support.
This study makes a significant contribution to the body of empirical literature on
super-utilizers by demonstrating high opioid use in this population. Specifically, we
found that about 69% had filled >1 opioid medications in the fourth period. A substantial
amount of opioid utilization is likely driven by the high prevalence of chronic pain in the
super-utilizers as documented in a previous study.57 In our adjusted models, although
insignificant, we found that super-utilizers with recent opioids use make less use of ED
and inpatient services, especially among elderly Medicare patients. A recent study found
that opioid use is common after hospitalization among Medicare beneficiaries.92 Future
studies should investigate the reasons behind this finding as this can shed some light on
the patterns of high opioid use in this population.
Among other factors, non-Hispanic blacks and dual beneficiaries receiving LICS
were at risk for higher utilization. These findings are consistent with previous studies
conducted on Medicare patients.95,96 For instance, Joynt and colleagues examined racial
disparities in readmissions among elderly Medicare beneficiaries and found that black
patients were more likely to be readmitted after hospitalization for myocardial infarction,
congestive heart failure, and pneumonia.96 Furthermore, it has been well established that
dual beneficiaries have higher utilization and account for disproportionate share of
Medicare spending. Our findings highlight the vulnerability of these groups and the need
for greater attention.
This study has important implications for policy makers and institutions involved
in improving the quality of care and reducing health care costs for super-utilizers. Our
study findings suggest that improving medication adherence may be critical in reducing
inpatient and ED use. Given these findings, hospitals, managed care organizations, and
payers should engage in programs aimed at improving medication adherence in superutilizing population. Successful medication management interventions have used multiple
strategies, including pharmacist-provided medication therapy management, specialized
medication packaging, motivational strategies, and telemonitoring, among others.1,40,43,44
However, targeting interventions to patients with multiple chronic conditions, complex
medication regimens, and high health care utilization, needs a comprehensive multimodal
approach that can address patient and system-level barriers to achieving optimal
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medication adherence. In our prior work, we found that during care transitions processes
from the hospital to the community setting, super-utilizers were at high risk for drug
therapy problems and medication discrepancies, which may result in poor adherence.13
This cyclical process of nonadherence leading to increased frequency of hospitalizations,
causing drug therapy problems and medication discrepancies in super-utilizers, can have
detrimental effects on their health outcomes. Our findings showing high prevalence of
mental illness, substance use disorder, and opioid medication use have highlighted the
importance of monitoring for signs of opioid abuse, and having a strong social support
and mental health facilities for vulnerable super-utilizing populations who have complex
medical and social needs. Patients with complex behavioral health issues could benefit
from greater coordination of health care providers and health care systems and having
access to high-quality mental health services.
Our study is also subject to several limitations. First, although pharmacy fill data
is widely used to assess medication adherence, we cannot be certain that patients who fill
medications are also using them appropriately. Second, many patients may have been
long-term users of essential chronic medications, and we may have missed a few if they
did not have any medication fill during the 2-year evaluation period. Third, the PDC
measure for calculating adherence is an indirect method and may not accurately capture
medication use and is likely to be biased for inhalation products that are prescribed for
Asthma and COPD. Fourth, since this study is based on super-utilizers living in
Memphis, TN, the study findings may only be generalizable to similar populations and
similar settings across the country. Finally, although our fixed-effects models addressed
potential endogeneity, we cannot conclude with certainty that these associations were
causal.
CONCLUSION
In summary, medication nonadherence was associated with increased incidence of
hospitalizations and ED use, both overall and across diabetes, cardiovascular, and
COPD/asthma therapy classes. Additionally, the effects of nonadherence on ED visits
were more pronounced for younger Medicare beneficiaries. Among other important
factors, mental illness, tobacco use disorder, non-Hispanic black race, and dual eligible
beneficiaries with low-income subsidy predicted higher inpatient and ED use.
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CHAPTER 4. EFFECT OF A CARE TRANSITIONS PROGRAM ON
MEDICATION USE AND ADHERENCE AMONG SUPER-UTILIZERS WITH
CHRONIC CONDITIONS
BACKGROUND
Super-utilizers are patients who have high health care costs from recurring,
preventable inpatient or emergency department (ED) visits. A decade ago Dr. Jeffrey
Brenner, a physician from Camden, NJ, had identified that a small group of patients
accounted for a bulk of health care costs.55 Since then the interest in super-utilizers has
increased among policymakers, health systems, and researchers. Super-utilizers represent
only 3 to 10% of Medicare and Medicaid population, but are responsible for 30 to 50% of
the health care spending.56 They often face complex medical and social issues including
multiple chronic conditions (MCC), mental health illnesses, substance abuse, issues with
transportation, low health literacy, and low social support, among others.56-58 During care
transitions processes, super-utilizers often experience difficulty in medication
management; medication discrepancies and drug therapy problems being key factors in
making these care transitions complex.13,18,97. Managing medication-related adverse
events and improving medication adherence among super-utilizers may be critical for
hospitals and payers since improving adherence to essential chronic medications is
crucial for reducing preventable hospital readmissions.4,5,39 Given the widespread
recognition that drug therapy problems and medication nonadherence play a major role in
readmissions, care transitions models with a focus on medication management are being
increasingly explored to reduce drug therapy problems and improve medication
adherence.17,19,54
Pharmacists can play a central role in care transitions models focused on
medication management. To date, studies evaluating the impact of pharmacist-led
interventions on medication errors, medication adherence, and health care utilization after
hospital discharge have shown mixed results.17,19,49,54,98,99 For example, Kripalani and
colleagues found that among patients hospitalized with acute coronary syndromes or
acute decompensated heart failure, the pharmacist-led interventions did not significantly
reduce medication errors after hospital discharge.19 Schnipper and colleagues found that
pharmacist-provided interventions for patients discharged home from the general
medicine service was associated with a lower rate of preventable adverse drug events
(ADE). However, there was no significant effect of these interventions on overall ADE or
total health care utilization.17 Another study by Ho and colleagues found that among
patients with acute coronary syndrome, multifaceted pharmacist-led interventions
increased adherence to cardioprotective agents one year following hospital discharge.
Nonetheless, the intervention did not have any positive effect on blood pressure and lowdensity lipoprotein cholesterol levels.49 Except for the study by Ho and colleagues, the
interventions were mainly provided in the hospital setting. Moreover, despite increased
interest in super-utilizers and increased focus on reducing their disproportionate health
care utilization and costs, there is a lack of evidence on whether pharmacist-led intensive
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medication management interventions as part of a care transitions program can improve
medication use and adherence in super-utilizers with chronic conditions.
This study was an evaluation of the SafeMed Program, an innovative care
transitions program targeting super-utilizers with a major focus on medication
management.60 Pharmacist-led interventions as part of the SafeMed Program included the
following: comprehensive medication review (CMR), targeted medication therapy
management (MTM), enhanced discharge planning, home visits, phone follow-ups,
medication reconciliation during discharge and post-discharge, and care coordination
with patient’s physicians.13 The objective of this study was to examine the impact of the
SafeMed Program on medication utilization and adherence among a vulnerable, publicly
insured, super-utilizing cohort of patients admitted to a local hospital system in Memphis,
TN. The study findings may have a positive impact by highlighting the importance of
innovative care transitions medication management interventions that can improve
adherence among vulnerable super-utilizers, who can benefit the most from such
interventions.
METHODS
Design and Setting
This study used a quasi-experimental study design to examine the effectiveness of
the SafeMed Program on medication adherence among SafeMed participants compared
with patients in a control group using difference in differences (DID) approach. The
SafeMed program targeted publicly insured super-utilizers with chronic conditions from
medically underserved areas admitted to a non-profit hospital system in Memphis, TN
from February 1, 2013 to May 1, 2015.60 We analyzed Medicare and Tennessee Medicaid
claims data for this study. We had Tennessee Medicaid claims data for beneficiaries
meeting the SafeMed Program eligibility criteria for the entire program duration—from
February 1, 2013 to May 1, 2015. However, since the Medicare Part D data files were
incomplete at the time of this study, we used Medicare claims data only for the period
from February 1, 2013 to June 30, 2014. The program enrollment occurred during an
inpatient admission or an observation stay (index admission), after which the patients
who agreed to participate in the SafeMed Program were provided the various medication
management interventions for a minimum of 45 days following hospital discharge. For
this study evaluation, program participants and controls were followed for 6-month post
index discharge and 6 months prior to their index admission.
Population
The SafeMed Program eligibility was based on the following inclusion criteria: 1)
adults aged 18 years or older with continuous Medicare or Medicaid enrollment, 2) >2
hospital admissions in the past six months OR 1 inpatient admission and >2 emergency
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department (ED) visits in the six months prior to the index admission, and 3) diagnosis of
>1 of the following chronic conditions: hypertension, congestive heart failure (CHF),
coronary artery disease (CAD), diabetes mellitus, asthma, or chronic obstructive
pulmonary disease (COPD) in the baseline period. The International Classification of
Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes for the inclusion
criteria are listed in Appendix A, Table A-1.
Patients were excluded from the SafeMed Program if the primary reason for index
admission was related to cancer, pregnancy, or a surgical procedure for an acute problem
following the approach of Jencks and colleagues recognizing that utilization for these
conditions is less likely to be affected by outpatient chronic disease care or medication
management.77 Patients were also excluded if they had diagnoses of active psychosis,
drug abuse, substance abuse or suicidal ideation during the index admission, or if they
were discharged to a skilled nursing facility or hospice care because of evidence
suggesting that high utilization in these patient populations may be less amenable to
outpatient intervention.57 The ICD-9-CM codes and diagnosis-related group (DRG) codes
for the exclusion criteria are listed in a previous paper by Harris and colleagues.57
The control group included patients deemed eligible for the SafeMed Program
based on the eligibility criteria listed above, but who either: 1) declined to participate in
the program when they were offered the chance to participate, or 2) were discharged from
the hospital before the SafeMed staff had an opportunity to screen them and offer
participation, or 3) met basic SafeMed eligibility requirements based on a daily eligibility
report generated by the hospital system. We used Medicare and Medicaid claims data to
confirm further their eligibility based on the inclusion and exclusion criteria.
Of the 1,778 eligible patients meeting SafeMed inclusion and exclusion criteria
above, the final sample included the 1,122 (63.1%) who were continuously eligible for
Medicare Part D or had drug coverage from Medicaid and filled at least one of seventeen
drug classes during both pre-and post-periods. These drug classes included angiotensinconverting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARB), statins,
antiplatelet agents, beta-blockers, calcium channel blockers, diuretics, alpha-1 blockers,
central alpha-2 agonists, direct vasodilators, sulfonylureas, biguanides,
thiazolidinediones, meglitinides, dipeptidyl peptidase-4 inhibitors, anticholinergic
inhalers, inhaled corticosteroids alone or in combination with long-acting beta-agonists
(LABA), and other COPD/asthma medications (theophylline and leukotriene modifiers).
Program Description
The program used a diverse team of health care providers, including pharmacists
and pharmacy technicians as key team members. The SafeMed medication management
team, including two program pharmacists and two certified pharmacy technicians,
worked together to provide medication management services to SafeMed enrollees. As
previously described, patient enrollment occurred during an inpatient admission or an
observation stay, during which the SafeMed enrollees received an inpatient CMR from
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the pharmacists. SafeMed pharmacists reviewed the drug profile with patients or their
caregivers to identify any drug therapy problems. They made appropriate
recommendations and worked closely with the physicians and alerted them of the
identified drug therapy problems. Additionally, as part of the discharge planning,
pharmacists provided and discussed a personalized patient-friendly medication list with
patients, explained the purpose of each medication, dosing instructions, and potential side
effects. The role of the pharmacy technician was to identify any potential drug therapy
problems during home visits and phone follow-ups, who then coordinated with the
pharmacist to resolve any medication-related issues.
Medication reconciliation, which involved comparing patient’s discharge
medication orders to all the medications that the patient had been taking, was performed
by pharmacy technicians during the first and second home visits that happened within 3
days and 3 weeks of discharge, respectively. This ensured that any omissions,
duplications, potential drug interactions, or any potential dosing errors and adverse events
were identified and reported to the pharmacist. During home visits, pharmacy technicians
also educated patients on drug disposal, filling pill boxes, and self-management
guidelines. A minimum of two phone follow-ups were performed during the second and
the fourth week of discharge. During each phone follow-up, pharmacy technicians
identified barriers to using any prescribed medications and potential drug therapy
problems. Pharmacists then followed-up with patients who were identified as having drug
therapy problems and provided targeted MTM by phone and outpatient CMR to further
resolve any medication-related issues and to improve the overall effectiveness of their
medication regimen. Follow-up outpatient CMR was provided to patients during the fifth
week of the SafeMed Program, after the completion of home visits and phone follow-ups
by pharmacy technicians. The overall interventions including pharmacist-led medication
management interventions provided at different time points have been shown in
Appendix C, Table C-1.76
Outcome Variables
Medication adherence
Medication adherence was measured using the interval-based proportion of days
covered (PDC), defined as the percentage of days during the observation period during
which the participants or controls had their recommended prescribed medications on
hand. PDC was expressed as percentage capped at 100% and was calculated for the 6month baseline period and the 6-month evaluation period. We measured PDC for the
seventeen drug classes mentioned above. Drugs that belonged to the same therapeutic
class (example, amlodipine, and nifedipine in the calcium channel blockers) were
considered interchangeable. Additionally, based on the evidence-based guideline, ACE
inhibitors and ARB were considered a single class for this study.78 Antiplatelet agents did
not include aspirins because aspirins are usually purchased without a prescription (overthe-counter) and are not included in Part D claims data. Moreover, we did not include
insulin since the days’ supply information on this drug class is not accurate.79
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Using this approach, the numerator was defined as the number of days of
medication supplied between the first and last prescription in a period and the
denominator was defined as the number of days during the interval from the index date,
which was the first day of the medication fill in a given 6-month period, to the last day of
that period. Any duration of inpatient hospitalization was subtracted from the PDC
denominator. The average PDC measure was calculated at the patient-level by adding the
PDC for each drug class and then dividing by the number of drug class used by the
patient. We then classified patients as adherent if they had PDC of at least 80% over the
follow-up and pre-intervention period. The main outcome variable was the overall binary
adherence classification. Adherence was also measured based on therapy-specific
medication adherence classifications, which included diabetes, cardiovascular, and
COPD/asthma medications. Additionally, PDC was measured in the patient sample
stratified by age, insurance type and number of comorbidities.
Medication use
We also examined whether the intervention had any positive effect on medication
use based on a patient’s diagnosis. Following were the medication use measures: 1)
patients diagnosed with diabetes using any oral diabetes medications, 2) patients
diagnosed with COPD or asthma using any long-term controller medications, and 3)
patients diagnosed with CHF using any ACE/ARB medications.
Independent Variables
The main independent variables included a binary indicator of whether patients
received the SafeMed intervention (1=Participant, 0=Control) and a binary indicator of
time (1=post-intervention period, 0=pre-intervention period). Additionally, the
multivariate models controlled for the following covariates: age, gender, race, and
insurance, measured at the index admission. Covariates assessed for the 6-month baseline
period included diagnosis of depression or anxiety, and disease burden measured using
the University of Manitoba SAS Macro for Charlson comorbidity index.80
Statistical Analysis
Propensity score matching was conducted to account for the observed differences
between the intervention and the control group. The propensity score, which was
estimated using a logistic regression model, was defined as the patient’s probability of
receiving the SafeMed intervention versus no intervention and was conditional on the
measured baseline covariates that included age, gender, race, insurance, qualifying
chronic conditions, Charlson comorbidity index, and anxiety/depression. Propensity score
matching paired each participant of the intervention group to 2 controls within calipers of
0.01 units on the propensity score scale.100 All analyses were conducted on propensity
score-matched samples. Baseline differences between study participants and controls
were estimated using chi-square tests and t-tests analyses. For multivariate analyses, we
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used logistic regression with DID approach to estimate changes in average probability of
adherence or medication use from the pre-intervention period to post-intervention period
that differed from concurrent changes in the control group, after controlling for
confounding variables. While DID models with only one pre-intervention and one postintervention observation cannot control for differences in time trends in the SafeMed
enrollees and controls, it does allow us to control for permanent unobserved differences
between the groups. All data analyses were conducted using SAS 9.4 and STATA 13.
Variables in the multivariate models with P<0.05 were considered significant.
RESULTS
Table 4-1 provides the baseline characteristics for the SafeMed enrollees and
controls before and after applying propensity score matching. Before propensity score
matching, enrollees (N=152) and controls (N=970) were different on several measures.
Compared with controls, the enrollees were more likely to be younger (52.2 vs. 59.7,
P<0.001), black (77% vs. 68.7%, P<0.001), and Medicaid only beneficiaries (52% vs.
32.7%, P<0.001). Additionally, compared with controls, enrollees were more likely to
have diabetes (71.1% vs. 61.2%, P=0.020), asthma (42.1% vs. 29.5%, P=0.002), COPD
(58.6% vs. 43.2%, P=0.004), and lower mean Charlson comorbidity index (4.4 vs. 4.8,
P=0.042). After applying propensity score matching, although the sample size reduced
from 1,122 to 456, the intervention (N=152) and the control group (N=304) were similar
across all sociodemographic and clinical factors.
The patterns of mean PDC among the enrollees and controls during pre- and postintervention periods is shown in Figure 4-1. The mean PDC was lower in enrollees than
controls in both pre- and post-intervention periods. Additionally, the mean PDC for
enrollees and controls decreased progressively from the pre- to the post-intervention
period. Among enrollees, the mean PDC was 63.8% in the pre-intervention period and
declined to 61.8% in the post-intervention period. Similarly, among controls, the mean
PDC was 70.5% in the pre-intervention period and declined to 65.6% in the postintervention period. The proportion of adherent patients (PDC >80%) among enrollees
declined from 34.2% in the pre-intervention period to 25.0% in the post-intervention
period, while among controls, this proportion declined from 41.1% to 32.6% (results not
shown).
Table 4-2 shows the DID results for overall medication adherence and therapyspecific adherence. In the 6-month period following SafeMed index discharge, overall
adherence decreased in both enrollees and controls. Although the magnitude of decline in
adherence was greater among controls than enrollees, this difference was not statistically
significant. DID estimate for overall adherence was +5 percentage points (DID: 0.05;
Confidence Interval (CI), -0.28, 0.39). Similar patterns were observed for diabetes drug
class where the DID estimate was +38 percentage points, but the results were not
statistically significant (DID: 0.38; CI, -0.94, 1.69). For COPD/asthma medication class,
following the SafeMed intervention, adherence increased in enrollees, whereas decreased
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Table 4-1.

Baseline Characteristics of the Study Population

Characteristic
Age, mean (SD)
Age>65
Female sex
Race
Non-Hispanic White
Black
Hispanic/Others
Insurance
Medicare Only
Medicaid Only
Dual Eligible
Qualifying chronic conditions
Diabetes
Hypertension
Congestive heart failure
Coronary artery disease
Asthma
COPD
Anxiety or Depression
Charlson comorbidity index,
mean (SD)
Total amount paid by
Medicare or TennCare, mean
(SD)

Before Matching
Enrollees
Controls
N=152
N=970
52.2 (13.7)
59.7 (15.2)
34 (22.5)
359 (37.1)
97 (63.8)
585 (60.3)

P
Value
<0.001
<0.001
0.410

After Matching
Enrollees
Controls
N=152
N=304
55.2 (13.7)
56.0 (15.2)
39 (25.7)
87 (28.6)
97 (63.8)
186 (61.2)

P
Value
0.580
0.505
0.585

16 (10.5)
117 (77.0)
19 (12.5)

241 (24.9)
666 (68.7)
63 (6.5)

<0.001

16 (10.5)
117 (77.0)
19 (12.5)

27 (8.9)
242 (79.6)
35 (11.5)

0.793

18 (11.8)
79 (52.0)
55 (36.2)

217 (22.4)
317 (32.7)
436 (45.0)

<0.001

18 (11.8)
79 (52.0)
55 (36.2)

41 (13.5)
131 (43.1)
132 (43.4)

0.198

108 (71.1)
147 (96.7)
104 (68.4)
83 (54.6)
64 (42.1)
89 (58.6)
39 (25.7)
4.4 (2.2)

594 (61.2)
945 (97.4)
606 (62.5)
509 (52.5)
286 (29.5)
419 (43.2)
312 (32.2)
4.8 (2.7)

0.020
0.613
0.157
0.625
0.002
0.004
0.108
0.042

108 (71.1)
147 (96.7)
104 (68.4)
83 (54.6)
64 (42.1)
83 (54.6)
39 (25.7)
4.4 (2.2)

209 (68.8)
293 (96.4)
213 (70.1)
156 (51.3)
111 (36.5)
156 (51.3)
85 (28.0)
4.4 (2.3)

0.615
0.857
0.719
0.507
0.247
0.507
0.602
0.965

340.9 (509.7)

288.7 (522.3)

0.251

340.9 (509.7)

325.6 (617.8)

0.792
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Figure 4-1. Average Proportion of Days Covered in the Pre- and PostIntervention Period
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Table 4-2.
Multivariate Difference-in-Differences Analysis Comparing Medication Adherence Between SafeMed
Intervention Group and Control Group (by Therapy Class)
Drug Class
All Drug Classes
Diabetes
CVD
COPD/Asthma

SafeMed
Group
(T)
0.58
0.98
0.73
0.36

Pre-Intervention Period
Control Difference
95% CI
Group
(T-C)
(C)
0.80
-0.22
-0.50,0.05
1.63
-0.65
-0.71,0.42
0.81
-0.08
-0.40,0.23
0.94
-0.58
-1.10,-0.05

SafeMed
Group
(T)
0.36
0.75
0.50
0.45

Post-Intervention Period
Control Difference
95% CI
Group
(T-C)
(C)
0.53
-0.17
-0.36,0.02
1.02
-0.27
-1.04,0.51
0.63
-0.13
-0.36,0.11
0.74
-0.29
-0.75,0.16

Difference
in
Differences
0.05
0.38
-0.04
0.28

95% CI
-0.28,0.39
-0.94,1.69
-0.40,0.32
-0.40,0.96

Significant at P < .05
Adherence estimates are probability-scale predictions, adjusted for age, race, gender, insurance, Charlson comorbidity index, and
anxiety or depression.
CVD: Cardiovascular disease
All drug classes: N=912
Diabetes drug class (oral diabetes medications): N=192
CVD drug class: N=870
COPD/asthma drug class (long-term controller medications): N=270
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in controls. However, this positive effect of the intervention was not statistically
significant (DID: 0.28; CI, -0.40, 0.96).
Table 4-3 shows the DID results among various sub-group populations. We found
similar adherence trends across all sub-group populations. Following the SafeMed
intervention, there was a decline in overall adherence in both enrollees and controls. For
patients >65 years of age, Medicare only, and those with <4 comorbidities, there was a
greater decline in overall adherence among controls, which is indicated by positive DID
estimates. However, for patients <65 years of age, Medicaid only, dual eligibles, and
those with >4 comorbidities, there was a greater decline in overall adherence among
enrollees, which is indicated by negative DID estimates. None of the DID estimates were
statistically significant.
Figure 4-2 shows DID results for >1 diabetes medication fill among patients
diagnosed with diabetes. Following intervention, the probability of filling >1 oral
diabetes medications increased only among enrollees, which is indicated by a positive
DID estimate (DID: 0.19; CI: -0.05, 0.42). Similarly, among patients diagnosed with
COPD or asthma, the probability of using >1 long-term controller medication increased
among enrollees—indicated by a positive DID estimate (DID: 0.38; CI: -0.30, 1.05)
(Figure 4-3). However, among patients diagnosed with CHF, after intervention the
probability of filling >1 COPD/asthma medications decreased among enrollees—
indicated by a negative DID estimate (DID: -0.86; CI: -1.93, 0.21) (Figure 4-4).
DISCUSSION
In this quasi-experimental study, we found that medication adherence was suboptimal among SafeMed enrollees and controls, and it decreased further from the preintervention period to the post-intervention period. Combining the study findings from
the analyses conducted on the 2-year baseline Medicare data (Chapter 2 and Chapter 3),
this study shows a further decreasing trend in adherence over time among super-utilizers.
Overall, the pharmacist-led medication management interventions as part of the SafeMed
Program did not improve medication adherence in vulnerable super-utilizers with chronic
conditions. However, for some sub-group populations, the intervention may have ensured
that the decline in the probability of being adherent was not as low as it would have been
in the absence of the intervention. Furthermore, although statistically insignificant, the
SafeMed intervention had a positive impact on the use of COPD/asthma controller
medications and oral diabetes medications.
Considering the lack of statistical significance in the findings from this quasiexperimental study, an important question that arises is why did this the intervention not
bring about significant improvements in enrollees’ medication-related outcomes? As care
transitions programs for super-utilizers are becoming more popular, it is important to
understand whether medication management interventions as part of care transitions
programs are successful in improving medication adherence among super-utilizers who
are at a greater risk of experiencing drug therapy problems. The low rates of medication
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Table 4-3.
Multivariate Difference-in-Differences Analysis Comparing Medication Adherence Between SafeMed
Intervention Group and Control Group (by Subgroups)
Measure
Age<65 years
Age>65 years
Medicare Only
Medicaid Only
Dual Eligible
<4 Charlson
Comorbidity Index
>4 Charlson
Comorbidity Index

SafeMed
Group
(T)
0.49
0.91
0.64
0.45
0.66
0.38
0.68

Pre-Intervention Period
Control Difference 95% CI
Group
(T-C)
(C)
0.62
-0.13
-0.40,0.14
1.52
-0.60
-1.64,0.43
1.41
-0.78
-1.8,0.30
0.47
-0.01
-0.29,0.26
0.95
-0.29
-0.79,0.22
0.65
-0.27
-0.62,0.08
0.87

-0.19

SafeMed
Group
(T)
0.27
0.68
0.50
0.22
0.51
0.19

-0.57,0.19

0.47

Post-Intervention Period
Control Difference
95% CI
Group
(T-C)
(C)
0.49
-0.22
-0.41,-0.03
0.64
0.04
-0.50,0.57
0.46
0.04
-0.55,0.62
0.30
-0.07
-0.26,0.11
0.83
-0.31
-0.73,0.10
0.30
-0.12
-0.32,0.09
0.70

-0.23

-0.52,0.07

Difference
in
Differences
-0.09
0.64
0.81
-0.06
-0.03
0.16

95% CI
-0.42,0.24
-0.50,1.78
-0.34,1.96
-0.37,0.25
-0.62,0.57
-0.21,0.52

-0.04

-0.48,0.41

Significant at P < .05
Adherence estimates are probability-scale predictions, adjusted for age, race, gender, insurance, Charlson comorbidity index, and
anxiety or depression.
Sample for Age <65 years: N=660
Sample for Age>65 years: N=252
Sample for Medicare Only: N=118
Sample for TennCare Only: N=420
Sample for Dual Eligible: N=374
Sample for <4 Charson comorbidity index: N=338
Sample for >4 Charson comorbidity index: N=574
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Figure 4-2. Multivariate Difference-in-Differences Analysis for ≥1 Oral Diabetes
Medication Fill in Patients Diagnosed with Diabetes (N=634)
Note: Significant at P < .05. Adherence estimates are probability-scale predictions,
adjusted for age, race, gender, insurance, Charlson comorbidity index, and anxiety or
depression.
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Figure 4-3. Multivariate Difference-in-Differences Analysis for ≥1 Long-Term
Controller Medication Fill in Patients Diagnosed with COPD or Asthma (N=582)
Note: Significant at P < .05. Adherence estimates are probability-scale predictions,
adjusted for age, race, gender, insurance, Charlson comorbidity index, and anxiety or
depression.
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Figure 4-4. Multivariate Difference-in-Differences Analysis for ≥1 ACE/ARB Fill
in Patients Diagnosed with CHF (N=634)
Note: Significant at P < .05. Adherence estimates are probability-scale predictions,
adjusted for age, race, gender, insurance, Charlson comorbidity index, and anxiety or
depression.
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adherence, even after intensive discharge preparation, planning, education, and care
coordination services through the pharmacist-led medication management interventions,
suggests that intensive investment in medication management interventions in this
vulnerable population may not be sufficient. The study findings indicate that especially
among patients <65 years of age, dual eligible beneficiaries, Medicaid beneficiaries, and
those with multimorbidity, positive outcomes from interventions influencing patient
behavior are difficult to achieve. Medication management interventions alone may not
work for these high-risk patients and there may be other important barriers that need to be
addressed to improve medication adherence in these high-risk sub-group populations.
Drug costs are one such factor that may contribute to sub-optimal medication
adherence in super-utilizers, specifically among Medicaid and dual eligibles. Choudhry
and colleagues found that eliminating out-of-pocket costs improved medication
adherence in patients discharged after myocardial infarction.101 In our prior work on
super-utilizers, patients experiencing high rates of medication discrepancies reported one
of the major contributors to post-discharge medication discrepancies being difficulty in
paying for medications.13 Furthermore, in our previous study (Chapter 2), we found lower
adherence for dual eligible beneficiaries receiving low-income subsidy. These are strong
indications that current medication cost subsidy amounts may not be sufficient to achieve
optimal adherence, and cost and affordability continue to remain significant barriers
among this high-risk patient population. Additional barriers to post-discharge medication
discrepancies reported by SafeMed enrollees in our previous study included
transportation and unavailability of needed prescription drugs before discharge.13 Future
interventions and their evaluations should explore alternative approaches to increasing
access to essential medications, especially for Medicaid and dual eligible beneficiaries,
such as providing bedside delivery, or providing essential medications at zero out-ofpocket costs for patients. At policy-level, increasing days’ supply for essential chronic
medications may help in improving adherence in this high-risk population.
Results of studies evaluating the impact of pharmacist-led interventions during
care transitions on medication-related outcomes have been mixed.17,19,49,54,98,102
Consistent with our results, few studies examining the impact of care transitions
programs on medication-related outcomes did not find any significant effect on
medication-related outcomes. For instance, Kripalani and colleagues did not find any
positive effect of pharmacist-led interventions on post discharge medication errors in
patients with acute coronary syndromes or acute decompensated heart failure.19
Additionally, in a sample of patients discharged to home and at high risk for medicationrelated problems, Walker and colleagues found that although pharmacist interventions
improved quality of patient’s discharge by identifying medication discrepancies, there
was no effect on hospital readmissions and ED visits.54 A direct comparison with their
findings is limited by the fact that our study focused explicitly on high-risk superutilizing patients residing in medically underserved areas. Moreover, our interventions
were not only provided during hospital discharge but also extended beyond hospital
discharge into the community. Ho and colleagues, who targeted patients from the
Department of Veteran Affairs, found a positive impact of the post-discharge pharmacistled interventions on adherence measured over a period or 1 year.49 The different patient
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populations and variations in program components and time frame for measuring
adherence may account for differences in results. Our study findings suggest that superutilizers are a complex patient population to intervene and extending medication
management services even to their homes may face significant challenges in improving
their adherence to needed life-saving medications.
Our results have important implications for health care systems striving to
improve medication adherence and overall quality of care for vulnerable super-utilizers.
Our analysis showed that adherence was suboptimal among super-utilizers and it declined
over time. Furthermore, the study suggests that certain patient populations such as elderly
Medicare beneficiaries and patients with lower comorbidities may be more amenable to
medication management interventions. However, we found that despite providing
intensive medication management interventions by a team of pharmacists and pharmacy
technicians, there was no positive effect on medication adherence. This indicates that
traditional medication management interventions during care transitions may not be
enough for these patients and other alternative strategies such as addressing social risk
factors and removing cost barriers may be needed to improve adherence in this
population. Moreover, our work represents a real-world scenario where the SafeMed staff
faced challenges in contacting and scheduling home visits and phone follow-ups with
patients during the early implementation phase of the program. Initially we could not
provide interventions to many patients. However, after extensive program improvement
efforts, there was a significant improvement in the intervention completion rates.60
Providing interventions to high-risk patient population is challenging and it is difficult to
achieve full program potential as anticipated in a real-world setting.
The negative effect of these medication management interventions on adherence
could be partly due to limitations of this study. One of the major limitations of this study
is the small sample size. Because of the incomplete Medicare Part D data on enrollees
and controls who became eligible from July 1, 2014 to May 1, 2015, the study findings
should be interpreted with caution. In future, we aim to reanalyze data for this study
using complete data for our Medicare-eligible enrollees and controls. Additionally, a key
question that arises is to what extent the negative findings are generalizable to other
settings? Because this study specifically focused on publicly insured super-utilizers living
in a medically underserved area with multimorbidity, it may only be generalizable to a
similar setting and a similar population. And, the efficacy of this intervention may differ
in less vulnerable populations. Furthermore, non-randomized studies may produce
selection bias; however, this study used propensity score matching, which minimized the
selection bias and unobserved confounding was minimized because of the quasiexperimental study design. Additionally, the follow-up period for this study was 6
months, which limits examination of long-term effects of the SafeMed program on
medication adherence. Finally, the PDC measure for calculating adherence was an
indirect method and may not accurately capture medication use and is likely to be biased
for inhalation products that are prescribed for asthma and COPD.
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CONCLUSION
In conclusion, the rates of medication adherence among super-utilizers with
chronic conditions were suboptimal, and adherence declined from the pre- to the postintervention period. Overall we found that medication management interventions as part
of the SafeMed Program did not improve adherence in enrollees compared to controls.
However, for patients diagnosed with COPD/asthma and diabetes, there were positive
medication use trends in favor of enrollees. The study findings suggest that intensive
medication management interventions provided beyond hospital discharge may not be
enough to achieving optimal adherence in super-utilizers with chronic conditions,
especially among Medicaid and dual eligible beneficiaries. Future studies are needed to
test alternative strategies focused on increasing access to essential chronic medications in
this vulnerable population.
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CHAPTER 5.

CONCLUSION

SUMMARY OF FINDINGS
Our retrospective panel data analysis of the 2-year data showed that the
proportion of patients who were nonadherent to their essential chronic disease
medications ranged from 45.7% to 58.4%, with the highest rate for COPD/Asthma
medications (54.3% to 64.4%). Nonadherence rates for cardiovascular and COPD/asthma
medications were higher in the fourth period than previous periods. Additionally, of
1,092 patients who met the super-utilizers criteria in the fourth period (qualifying period
for the SafeMed Program), only about 14% of them were super-utilizers in all previous
periods. The baseline characteristics demonstrated that majority of super-utilizers were
female, non-Hispanic black, dual eligible beneficiaries, and received low-income cost
sharing subsidy (LICS). Furthermore, the study subjects had high rates of mental illness,
substance use disorder, and opioid medication use. During the final 6-month period, 57%
of the study subjects were diagnosed with depression or anxiety or had filled
antidepressants or anxiolytics, 32% were diagnosed with tobacco use disorder, and 69%
had filled opioid medications. The multivariate analysis showed that all three major
factors—the predisposing, enabling, and need factors were associated with medication
nonadherence. The risk factors for medication nonadherence included age <65 years as a
predisposing factor, dual beneficiaries receiving LICS and higher number of unique
prescribers as enabling factors, and >4 opioid medications filled in the previous period as
a need factor. Mental illness was not significantly associated with medication
nonadherence in the multivariate analysis. Factors associated with lower odds of
nonadherence included number of different medications filled as a need factor and >1
physician office visits in the previous period as an enabling factor.
When examining the associations between medication nonadherence, and
inpatient and ED use, as part of the second aim of this dissertation, we found higher
incidences of inpatient hospitalizations and ED visits among beneficiaries who were not
adherent to their essential chronic medications. Specifically, we found that among elderly
Medicare beneficiaries, nonadherence was significantly associated with a 57% increase in
inpatient hospitalizations, and among non-elderly Medicare beneficiaries, nonadherence
was significantly associated with 41% increase in inpatient stays and 25% increase in ED
visits. Similar associations were found across all therapy classes examined (diabetes,
cardiovascular, and COPD/asthma) in both age groups. However, nonadherence to
diabetes and COPD/asthma drugs was not significantly associated with ED visits.
Furthermore, we found that while the effects of nonadherence on inpatient stays were
seen in both age groups, the effects of nonadherence on ED visits were more pronounced
for younger Medicare patients. The study findings were consistent with prior research on
Medicare population which showed nonadherence to be associated with higher incidence
of hospitalizations.6,39 However, unlike previous studies based on Medicare population,
this study focused specifically on super-utilizing Medicare patients with chronic
conditions and polypharmacy. Moreover, our study population was disproportionately
represented by dual beneficiaries <65 years of age, who had on average higher
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comorbidities and were more likely to be nonadherent to their essential chronic
medications than elderly patients. Given these differences, examining associations
separately in the two age groups may help researchers to target these high utilizing
patient populations better with medication management interventions.
Based on Andersen behavioral model of health services utilization, we found that
all three major categories—predisposing, enabling, and need factors were associated with
higher inpatient and ED utilization. Among need factors, mental illness was a risk factor
for higher utilization among elderly and substance use disorder was a risk factor for
higher inpatient utilization among non-elderly Medicare patients. Additionally, the
predisposing risk factor included non-Hispanic black race and the enabling risk factor
included dual LICS status.
Finally, as part of the third aim, this study examined the impact of the SafeMed
Program on medication utilization and adherence among study participants compared
with propensity-matched controls. The study found that the proportion of adherent
patients (PDC >80%) among enrollees declined from 34.2% in the pre-intervention
period to 25.0% in the post-intervention period, while among controls, this proportion
declined from 41.1% to 32.6%. Thus, medication adherence was suboptimal among
SafeMed enrollees and controls, and it decreased further from the pre-intervention period
to the post-intervention period. Combining the study findings from the analyses
conducted on the 2-year baseline Medicare data (Chapter 2 and Chapter 3), this study
shows a further decreasing trend in adherence over time among super-utilizers. The
multivariate analyses demonstrated that the pharmacist-led medication management
interventions as part of the SafeMed Program did not improve medication adherence in
vulnerable super-utilizers with chronic conditions. However, for some sub-group
populations including Medicare only beneficiaries, patients >65 years of age, and patients
with a lower number of comorbidities, the intervention may have ensured that the decline
in the probability of being adherent was not as low as it would have been in the absence
of the intervention. Furthermore, although statistically insignificant, the SafeMed
intervention had a positive impact on the use of COPD/asthma controller medications and
oral diabetes medications.
IMPLICATIONS FOR PRACTICE AND POLICY
This study has important implications for policy makers and institutions striving
to improve the quality of care and reducing health care utilization and costs for superutilizers with chronic conditions. The literature on super-utilizers is sparse and mainly
focuses on describing the population and their hospitalization patterns.56,57 This study is
the first to our knowledge to demonstrate the magnitude and importance of medication
nonadherence in vulnerable super-utilizers with chronic conditions. We not only found
high rates of nonadherence among super-utilizers but also saw an increase in the
nonadherence rates when patients had more frequent hospitalizations and ED visits. The
study findings suggest that medication nonadherence is a significant problem among
super-utilizers, and greater efforts may be needed to address this issue.
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The predisposing, enabling, and need-related risk factors for nonadherence
identified in this study may enable hospitals, accountable care organizations and managed
care organizations identify super-utilizing populations in need of medication management
interventions. Managing medication-related adverse events and improving medication
adherence among vulnerable super-utilizers is critical for hospitals and payers since 75%
of the hospital readmissions among Medicare population are considered potentially
preventable, resulting in $12 billion in unnecessary Medicare spending each year and
subjecting hospitals to readmission penalties.46 The study suggests that non-elderly
Medicare patients, dual beneficiaries receiving low-income subsidy, and patients using a
higher number of opioid medications are at greater risk for nonadherence. These highrisk patient populations may merit targeted interventions to support essential chronic
disease medication adherence. Despite receiving low-income subsidy, dual beneficiaries
were less likely to adhere to their therapy. This indicates that for super-utilizing lowincome dual beneficiaries, subsidies may not be sufficient to achieve optimal adherence,
and cost remains a significant barrier to achieving optimal adherence. Additionally,
highly statistically significant and large effect size of the association between age and
medication nonadherence demonstrates the need for better targeting of the non-elderly
Medicare group with medication management interventions. The study findings suggest
the importance of making routine visits to providers who can play a significant role in
helping patients to adhere to their essential chronic medications. And, it also highlights
the importance of reducing prescribing complexity in this high-risk patient population,
which may result in suboptimal adherence.
Our study findings further demonstrate that improving medication adherence—a
patient behavioral factor very amenable to change—may be critical in reducing inpatient
and ED use among Medicare super-utilizers with chronic conditions. In our previous
study, we found that during care transitions processes from the hospital to the community
setting, super-utilizers were at high risk for drug therapy problems and medication
discrepancies, which may result in suboptimal adherence.13 This cyclical process of
nonadherence leading to increased frequency of hospitalizations, causing drug therapy
problems and medication discrepancies in super-utilizers, can have detrimental effects on
their health outcomes. Given these findings, hospitals, managed care organizations, and
payers should engage in programs aimed at resolving drug therapy problems and
improving medication adherence in super-utilizing populations. By examining
associations for inpatient and ED use separately among non-elderly and elderly Medicare
beneficiaries, this study indicates that there are variations in effects within these groups.
For instance, mental illness was a risk factor for higher inpatient and ED utilization
among elderly, while substance use disorder was a risk factor for higher inpatient
utilization among younger patients. The study findings suggest that the two patient
groups may have different barriers and varying social and medical needs, which are
essential to be taken into consideration when designing interventions for these vulnerable
patients. Additionally, our findings highlight the vulnerability of non-Hispanic blacks and
low-income dual eligible beneficiaries who are at a higher risk for inpatient and ED
utilization. Policy makers need to pay greater attention to the needs of these patient
populations.
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Our study findings have important implications for health care systems striving to
improve medication adherence and overall quality of care for vulnerable super-utilizers.
The study found that despite providing intensive medication management interventions
by a team of pharmacists and pharmacy technicians, there was no positive effect on
medication adherence. However, for some sub-group populations (Medicare only, elderly
Medicare patients, and patients with lower comorbidity), the intervention may have
ensured that the decline in the probability of being adherent was not as low as it would
have been in the absence of the intervention. Furthermore, although statistically
insignificant, the SafeMed intervention had a positive impact on the use of COPD/asthma
controller medications and oral diabetes medications. These findings indicate that
traditional medication management interventions during care transitions may not be
sufficient for these high-risk patients and other alternative strategies such as addressing
social risk factors, and removing cost barriers may be needed to improve adherence,
especially among low-income dual beneficiaries, Medicaid enrollees, and patients with
higher comorbidity.
Finally, our findings showing a high prevalence of mental illness, substance use
disorder, and opioid medication use have highlighted the importance of monitoring for
signs of opioid abuse, and having a strong social support and mental health facilities for
vulnerable super-utilizing populations who have complex medical and social needs.
Patients with complex behavioral health issues could benefit from greater coordination of
health care providers and health care systems and having access to high-quality mental
health services.
IMPLICATIONS FOR FUTURE RESEARCH
We found that the pharmacist-led medication management interventions as part of
the SafeMed Program did not improve medication adherence in vulnerable super-utilizers
with chronic conditions. Drug costs are one such factor that may contribute to suboptimal
medication adherence in super-utilizers, specifically among low-income Medicaid and
dual eligible beneficiaries. In our previous study (Chapter 2, Chapter 3), we found lower
adherence and higher inpatient and ED utilization for dual eligible beneficiaries receiving
low-income subsidies. These are strong indications that current medication cost subsidy
amounts may not be sufficient to achieve optimal adherence and reduce utilization, and
cost and affordability continue to remain significant barriers among this high-risk patient
population. Additional barriers to post-discharge medication discrepancies reported by
SafeMed enrollees in our previous study included transportation and unavailability of
needed prescription drugs before discharge.13 Future interventions and their evaluations
should explore alternative approaches to increasing access to essential medications,
especially for low-income Medicaid and dual eligible beneficiaries, such as using hospital
outpatient pharmacies to fill medications, providing bedside delivery, providing essential
medications at zero out-of-pocket costs for patients, or increasing days’ supply for
essential chronic disease medications.
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We used Medicare claims data to examine the factors associated with medication
nonadherence (Aim 1) and the association between nonadherence and health care
utilization (Aim 2). The follow-up of this study would analyze these aims using
TennCare claims data to provide a comprehensive picture of the predictors of
nonadherence and the association between nonadherence and health care utilization in the
vulnerable TennCare population. Additionally, one of the major limitations of the study
examining the impact of the SafeMed Program on medication use and adherence was
small sample size. Because of the incomplete Medicare Part D data on enrollees and
controls who became eligible from July 1, 2014 to May 1, 2015, the study findings
should be interpreted with caution. In future, we aim to reanalyze data for this study
using complete data for Medicare-eligible enrollees and controls. Finally, costs associated
with medication nonadherence among super-utilizers are an important outcome and may
be of more interest to policymakers. The follow-up to this study would examine the costs,
including total costs and costs specific to health care services from the payer perspective.
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APPENDIX A. SUPPLEMENTAL MATERIALS FOR CHAPTER 2
Table A-1.
The International Classification of Diseases, Ninth Revision, Clinical
Modification [ICD-9-CM] Codes (Inclusion Criteria and Comorbidities)
Categories
Qualifying Chronic
Conditions
Hypertension

ICD-9-CM Codes

'36211','4010','4011','4019','40200','40201','40210','40211','40290','40291',
'40300','40301','40310','40311','40390','40391','40400','40401','40402','40403',
'40410','40411','40412','40413','40490','40491','40492','40493','40501','40509',
'40511', '40519','40591','40599','4372'

Congestive heart
failure

'39891','40201','40211','40291','40401','40403','40411','40413','40491','40493',
'4254','4255','4257','4258','4259','4280','4281','42820','42821','42822','42823',
'42830','42831','42832','42833','42840','42841','42842','42843','4289'

Coronary artery
disease

'41000', '41001', '41002', '41010', '41011','41012', '41020', '41021', '41022',
'41030', '41031', '41032', '41040', '41041', '41042', '41050','41051', '41052',
'41060', '41061', '41062', '41070','41071', '41072', '41080', '41081', '41082',
'41090', '41091', '41092', '4110', '4111', '41181', '41189', '412', '4130', '4131',
'4139', '41400', '41401', '41402','41403','41404','41405','41406','41407','41412',
'4142','4143','4148','4149','42979'

Diabetes mellitus

'24900','24901','24910','24911','24920','24921','24930','24931','24940','24941',
'24950','24951','24960','24961','24970','24971','24980','24981','24990','24991',
'25000','25001','25002','25003','25010','25011','25011','25012','25013','25020',
'2502','25022','25023','25030','25031','25032','25033','25040','25041','25042',
'25043','25050','25051','25052','25053','25060','25061','25062','25063','25070',
'25071','25072','25073','25080','25081','25082','25083','25090','25091','25092',
'25093','3572','36201','36202','36641'

Asthma

'49300','49301','49302','49310','49311','49312','49320','49321','49322','49381',
'49382','49390','49391','49392'

Chronic obstructive
pulmonary disease
Comorbidities
Anxiety or
depression

'490','4910','4911','49120','49121','49122','4918','4919','4920','4928','4940','4941,
'496'
'29384','30000','30001','30002','30009','30010','30020','30021','30022','30023',
'30029','3003','3005','30089','3009','3080','3081','3082','3083','3084','3089','3091,
'3130','3131','31321','31322','3133','31382','31383','29383','29620','29621','2962',
'29623','29624','29625','29626','29630','29631','29632','29633','29634','29635',
'29636','3004','311'

Tobacco use disorder

'3051'
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Table A-2. Medication Nonadherence to Essential Chronic Disease Medication by
Therapy Class
Therapy Class

Percent Nonadherent
(PDC <80%)

1. Diabetes medications
Period 1 (n=250)
Period 2 (n=269)
Period 3 (n=298)
Period 4 (n=300)
Overall (n=1,117 patient-periods)
2. Cardiovascular medications
Period 1 (n=933)
Period 2 (n=987)
Period 3 (n=1,010)
Period 4 (n=1,045)
Overall (n=3,955 patient-periods)
3. COPD/Asthma medications
Period 1 (n=169)
Period 2 (n=191)
Period 3 (n=216)
Period 4 (n=258)
Overall (n=834 patient-periods)
Diabetes, cardiovascular, and
COPD/Asthma meds combined
Period 1 (n=961)
Period 2 (n=1,011)
Period 3 (n=1,031)
Period 4 (n=1,060)
Overall (n=4,043 patient-periods)

41.2%
48.7%
58.4%
67.3%
53.3%
40.2%
53.1%
60.8%
66.0%
54.2%
54.4%
63.4%
66.7%
74.8%
64.4%
43.2%
56.1%
65.5%
72.8%
58.4%

COPD: chronic obstructive pulmonary disease.
COPD/Asthma medications included controller medications (anticholinergic inhalers,
inhaled corticosteroids alone or in combination with long-acting beta-agonists (LABA),
and other COPD/asthma medications (theophylline and leukotriene modifiers).
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Table A-3. Multivariate Associations with Medication Nonadherence Using
Alternative Proportion of Days Covered (PDC) Definition (N=2,999 Patient-Periods)

Characteristics
<65 years
Female
Non-Hispanic Black
Non-dual LIS
Dual LIS
Comorbidity
Charlson comorbidity index
Diagnosis of tobacco abuse disorder
Mental illness*
Medication related factors
No. of unique medications filled
Opioid Medication Use
0 opioid medication filled (Ref)
1 opioid medication filled
2-3 opioid medications filled
>4 opioid medications filled
Number of unique prescribers
Number of unique pharmacies
Health care utilization
>1 physician office visits

Nonadherence
Odds Ratio (95% CI)
P Value
2.14 (1.47-3.11)
<0.001
1.32 (0.94-1.85)
0.114
1.03 (0.71-1.51)
0.863
1.59 (0.88-2.86)
0.121
1.62 (1.07-2.44)
0.021
1.14 (1.07-1.20)
1.03 (0.70-1.52)
1.00 (0.71-1.41)

<0.001
0.867
0.987

0.93 (0.89-0.96)

<0.001

1.21 (0.85-1.74)
1.21 (0.83-1.78)
1.57 (0.94-2.08)
1.09 (1.03-1.16)
1.08 (0.95-1.21)

0.288
0.326
0.101
0.005
0.235

0.66 (0.45-0.98)

0.037

Significant at P<0.05. The model included lagged effects of comorbidity, therapy
complexity-related, and health care utilization factors.
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
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Table A-4. Multivariate Associations with Medication Nonadherence Using
Alternative PDC Criteria of ≥1 Medication Fill (N=3,062 Patient-Periods)
Characteristics
<65 years
Female
Non-Hispanic black
Non-dual LIS
Dual LIS
Comorbidity
Charlson comorbidity index
Diagnosis of tobacco abuse disorder
Mental illness
Medication related factors
Unique other medications filled
Opioid Medication Use
0 opioid medication filled (Ref)
1 opioid medication filled
2-3 opioid medications filled
>4 opioid medications filled
Unique prescribers
Unique pharmacies
Health care utilization
>1 physician office visits

Nonadherence
Odds Ratio (95% CI)
1.61 (1.23-2.10)
1.16 (0.90-1.49)
1.03 (0.78-1.37)
1.43 (0.95-2.17)
1.46 (1.08-1.98)

P Value
<0.001
0.242
0.830
0.089
0.014

1.00 (0.96-1.04)
0.96 (0.69-1.34)
0.76 (0.59-0.99)

0.905
0.828
0.040

0.96 (0.94-0.99)

0.003

1.23 (0.91-1.67)
1.17 (0.85-1.60)
1.62 (1.19-2.20)
1.09 (1.04-1.15)
1.04 (0.95-1.15)

0.177
0.344
0.002
<0.001
0.363

0.60 (0.45-0.82)

0.001

Significant at P<0.05. The model included lagged effects of comorbidity, therapy
complexity-related, and health care utilization factors.
*Mental illness was defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
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APPENDIX B. SUPPLEMENTAL MATERIALS FOR CHAPTER 3
Table B-1.
Multivariable Results for Inpatient Stays and ED Visits Among
Medicare Beneficiaries ≥65 years Using Random Effects Models (N=1,757 patientperiods)
Inpatient Stays
Characteristics
Overall medication nonadherence
Female
Non-Hispanic Black
Non-Dual LICS
Dual LICS
Comorbidity
Charlson comorbidity index
Mental illness
Tobacco abuse disorder
Opioid medication filled
0 opioid fill (ref)
1 opioid fill
2-3 opioid fill
>3 opioid fill
Number of unique medications
filled
Number of unique prescribers
>1 physician office visits

ED Visits

IRR (95% CI)
1.37 (1.23-1.52)
0.98 (0.88-1.09)
0.90 (0.79-1.01)
1.17 (0.96-1.42)
1.13 (1.00-1.28)

P Value
<0.001
0.691
0.083
0.120
0.045

IRR (95% CI)
1.20 (1.04-1.39)
1.04 (0.87-1.25)
1.40 (1.14-1.71)
1.31 (0.96-1.79)
1.44 (1.18-1.75)

P Value
0.016
0.660
0.001
0.093
<0.001

1.08 (1.06-1.09)
1.16 (1.03-1.30)
1.14 (0.99-1.32)

<0.001
0.015
0.065

1.06 (1.03-1.09)
1.47 (1.24-1.75)
1.03 (0.82-1.29)

<0.001
<0.001
0.818

1.02 (0.88-1.18)
0.92 (0.78-1.08)
0.92 (0.80-1.06)
1.01 (1.00-1.03)

0.830
0.331
0.263
0.118

1.05 (0.85-1.29)
1.08 (0.87-1.34)
0.95 (0.77-1.19)
0.98 (0.95-1.00)

0.661
0.495
0.670
0.047

1.01 (0.98-1.03)
0.91 (0.78-1.05)

0.697
0.192

1.07 (1.03-1.11)
4.06 (2.87-5.74)

<0.001
<0.001

Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department
visits.
We used random effects negative binomial models at patient level. The models included
lagged effects of all the above factors.
Overall medication nonadherence measured at patient-level was based on seventeen
index drug classes.
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
The multivariable model with inpatient stays as outcome included 1,227 patient-periods.
The multivariable model with ED visits as outcome included 986 patient-period.
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Table B-2.
Multivariable Results for Inpatient Stays and ED Visits Among
Medicare Beneficiaries <65 years Using Random Effects Models (N=1,242 patientperiods)
Inpatient Stays

ED Visits

Characteristics

IRR (95% CI)

P Value

IRR (95% CI)

P Value

Overall medication nonadherence
Female
Non-Hispanic Black
Non-Dual LICS
Dual LICS
Comorbidity
Charlson comorbidity index
Mental illness
Tobacco abuse disorder
Opioid medication filled
0 opioid fill (ref)
1 opioid fill
2-3 opioid fill
>3 opioid fill
Number of unique medications
filled
Number of unique prescribers
>1 physician office visits

1.37 (1.21-1.54)
1.04 (0.93-1.18)
1.06 (0.91-1.22)
1.15 (0.89-1.49)
1.07 (0.85-1.34)

<0.001
0.489
0.459
0.294
0.559

1.32 (1.13-1.54)
1.04 (0.85-1.27)
1.25 (0.98-1.58)
1.37 (0.88-2.13)
1.51 (1.03-2.21)

0.001
0.723
0.072
0.162
0.037

1.08 (1.06-1.09)
1.15 (1.02-1.31)
1.28 (1.13-1.44)

<0.001
0.026
<0.001

1.06 (1.03-1.09)
1.26 (1.05-1.53)
1.30 (1.07-1.58)

<0.001
0.015
0.008

0.84 (0.69-1.02)
0.99 (0.83-1.19)
1.16 (0.99-1.35)
0.99 (0.98-1.01)

0.076
0.948
0.064
0.783

0.83 (0.64-1.06)
0.89 (0.70-1.14)
1.05 (0.83-1.32)
1.01 (0.99-1.03)

0.133
0.356
0.694
0.535

1.02 (1.00-1.04)
0.80 (0.68-0.95)

0.075
0.009

1.05 (1.03-1.08)
1.82 (1.33-2.49)

<0.001
<0.001

Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department
visits.
We used random effects negative binomial models at patient level. The models included
lagged effects of all the above factors.
Overall medication nonadherence measured at patient-level was based on seventeen
index drug classes.
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
The multivariable model with inpatient stays as outcome included 1,227 patient-periods.
The multivariable model with ED visits as outcome included 986 patient-periods.
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Table B-3.
Multivariable Results for Inpatient Stays and Emergency Department
Visits Among Medicare Beneficiaries ≥65 years Using ≥1 Medication Fill Criteria
Inpatient Stays

ED Visits

Characteristics

IRR (95% CI)

P Value

IRR (95% CI)

P Value

Overall medication nonadherence
Comorbidity
Charlson comorbidity index
Mental illness
Diagnosis of tobacco use
disorder
Opioid medication filled
0 opioid fill (ref)
1 opioid fill
2-3 opioid fill
>3 opioid fill
Number of unique medications
filled
Number of unique prescribers
>1 physician office visit

1.78 (1.50-2.12)

<0.001

1.14 (0.94-1.39)

0.192

1.22 (1.17-1.28)
1.54 (1.20-1.96)
1.31 (0.91-1.86)

<0.001
0.001
0.145

1.17 (1.10-1.23)
1.46 (1.11-1.93)
0.69 (0.45-1.05)

<0.001
0.006
0.082

0.98 (0.78-1.22)
0.87 (0.67-1.12)
0.89 (0.66-1.20)
1.01 (0.99-1.03)

0.846
0.270
0.445
0.461

0.94 (0.73-1.20)
0.95 (0.73-1.25)
0.83 (0.57-1.19)
0.97 (0.94-1.00)

0.611
0.736
0.306
0.099

0.97 (0.92-1.02)
0.95 (0.70-1.28)

0.211
0.721

0.98 (0.93-1.04)
1.51 (0.94-2.42)

0.537
0.086

Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department visits
We used fixed effects negative binomial models at patient level. The models included
lagged effects of all the above factors.
Overall medication nonadherence measured at patient-level was based on seventeen
index drug classes.
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
The multivariable model with inpatient stays as outcome included 1,792 patient-periods.
The multivariable model with ED visits as outcome included 1,250 patient-periods.
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Table B-4.
Multivariable Results for Inpatient Stays and ED Visits Among
Medicare Beneficiaries <65 years Using ≥ Medication Fill Criteria
Inpatient Stays

ED Visits

Characteristics

IRR (95% CI)

P Value

IRR (95% CI)

P Value

Overall medication nonadherence
Comorbidity
Charlson comorbidity index
Mental illness
Diagnosis of tobacco use
disorder
Opioid medication filled
0 opioid fill (ref)
1 opioid fill
2-3 opioid fill
>3 opioid fill
Number of unique medications
filled
Number of unique prescribers
>1 physician office visit

1.46 (1.21-1.76)

<0.001

1.24 (1.01-1.51)

0.038

1.18 (1.13-1.23)
1.20 (0.92-1.56)
1.72 (1.26-2.34)

<0.001
0.184
0.001

1.11 (1.05-1.16)
1.18 (0.88-1.58)
1.30 (0.92-1.82)

<0.001
0.277
0.135

0.82 (0.64-1.06)
0.87 (0.67-1.14)
1.03 (0.75-1.43)
0.99 (0.96-1.01)

0.124
0.309
0.835
0.257

0.90 (0.69-1.18)
0.94 (0.71-1.25)
1.14 (0.81-1.62)
1.00 (0.98-1.02)

0.459
0.674
0.452
0.969

1.00 (0.96-1.03)
0.84 (0.64-1.10)

0.836
0.212

0.99 (0.96-1.03)
0.87 (0.62-1.22)

0.643
0.416

Significant at P<0.05. IRR: Incidence Rate Ratio. ED visits: Emergency department visits
We used fixed effects negative binomial models at patient level. The models included
lagged effects of all the above factors.
Overall medication nonadherence measured at patient-level was based on eighteen index
drug classes.
Mental illness is defined as >1 antidepressants or anxiolytics fill or diagnosis of
depression/anxiety.
The multivariable model with inpatient stays as outcome included 1,299 patient-periods.
The multivariable model with ED visits as outcome included 1,045 patient-period.
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APPENDIX C. SUPPLEMENTAL MATERIALS FOR CHAPTER 4
Table C-1.

Key SafeMed Care Transitions Interventions at Different Time Points

Week Activities
Hospital-based
0
Real time in-hospital identification, screening and
enrollment of eligible patients
Introduction of SafeMed team and initial patient
engagement with team and SafeMed program
Medication reconciliation and medication therapy
management
Enhanced discharge preparation, planning, education
and care coordination with outpatient providers and
community resources
Community-based
1
1st home visit within 72 hours
of discharge
Symptom and physical assessment
Medication reconciliation
Medication therapy management
Identify and address social needs
2
Phone follow-up and care coordination to ensure PCP
appointment within 14 days of enrollment
3
2nd home visit
Symptom and physical assessment
Medication reconciliation
Medication therapy management
Identify and address social needs
4
30-day phone follow-up
5
6

In-clinic comprehensive medication review (30-45 days
after enrollment)
SafeMed support session: monthly peer support group
and educational session open to all program participants
on an ongoing basis

Lead staff*
NP/RN
SafeMed team
Pharmacist, CPhTCHW
NP/RN, Pharmacist

LPN-CHW
CPhT-CHW
Pharmacist (remote)
SW/LPN-CHW
CPhT-CHW and
LPN-CHW
LPN-CHW
CPhT-CHW
Pharmacist (remote)
SW/LPN-CHW
CPhT-CHW and
LPN-CHW
Pharmacist (CPhTCHW to schedule)
SafeMed team

*The following abbreviations are used for lead SafeMed staff categories: nurse
practitioner (NP), registered nurse (RN), licensed practical nurse–community health
worker (LPN-CHW), certified pharmacy technician–community health worker (CPhTCHW), social worker (SW).
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